[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBEDyuhwQuyYhJemSm8kRYuWEWPfAb1-BleWogm4q8pE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":82,"rows":89},"Centre Hospitalier Universitaire Dijon",[4],486,false,93,30,10380573,58,312,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Stroke",9,{"name":18,"count":19},"Type 2 Diabetes",7,{"name":21,"count":19},"Diabetes",{"name":23,"count":24},"Septic Shock",6,{"name":26,"count":24},"Obesity",{"name":28,"count":29},"Colorectal Cancer",4,{"name":31,"count":29},"Schizophrenia",{"name":33,"count":29},"Colon Cancer",[35,40,45,50,55,60,64,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03875690","Benefit of a Flash Dose of Corticosteroids in Digestive Surgical Oncology: a Randomized, Double Blind, Placebo-controlled Trial","2024-02-29","Injection of methylprednisolone",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06753838","Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)","2025-12","Sampling of 3 additional BAPA tubes",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05568160","Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation","2026-03","Vasopressin",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03512132","Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy","2026-04","Blood samples",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04024774","Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases","2026-05","Biological samples",{"nctId":61,"briefTitle":62,"date":58,"intervention":63},"NCT06439355","Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis","Fasting blood test",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06875089","A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France","2026-06","pGS-NBS",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06430021","Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation","2026-12","blood sample",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04120701","CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II","2027-01","mFOLFOX6",{"nctId":80,"briefTitle":81,"date":77,"intervention":54},"NCT05939739","Study of the Value of Trio Exome Sequencing in the Etiological Assessment of Specific Non-syndromic Language and Learning Disorders",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,119,137,398,452,474,510,532,569,591,609,627,650,668,694,712,730,748,774,792,810,828,856,874,892,918,936,954,981,999,1025,1043,1069,1087,1112,1130,1148,1310,1489,1530,1561,1599,1617,1643,1661,1685,1703,1721,1745,1769,1793,1817,1837,1858,1878,1903,1930,1948,1966,1996,2018,2042,2060,2087,2105,2128,2152,2174,2200,2218,2244,2269,2287,2316,2334,2359,2377,2402,2420,2447,2465,2492,2510,2536,2554,2578,2604,2622,2649,2667,2691,2709,2727,2745,2770,2788,2811,2829,2855,2873,2895,2919,2937,2960,2986,3004,3030,3048,3071,3098,3123,3147,3173,3197,3223,3247,3284,3319,3358,3390,3425,3459,3493,3520,3538,3556,3584,3602,3620,3643,3661,3685,3708,3733,3751,3778,3804,3822,3846,3864,3890,3918,3936,3954,3972,3990,4014,4032,4056,4078,4102,4127,4153,4178,4196,4222,4249,4267,4294,4312,4337,4360,4385,4403,4428,4446,4472,4490,4508,4533,4557,4582,4606,4631,4656,4681,4706,4731,4756],{"intervention":91,"totalTrials":92,"cells":93},"Dexamethasone intravitreal implant",1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":117},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT04910503","Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema","RECRUITING",[87],"2030-04","2021-10-29",106,[114],"Diabetic Macular Edema",[91,116],"Fluocinolone Acetonide Intravitreal Implant",{"trials":118,"activeCount":96},[],{"intervention":116,"totalTrials":92,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":135},{"trials":122,"activeCount":96},[],{"trials":124,"activeCount":96},[],{"trials":126,"activeCount":96},[],{"trials":128,"activeCount":96},[],{"trials":130,"activeCount":92,"soonestReadout":110},[131],{"nctId":106,"briefTitle":107,"status":108,"phases":132,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":133,"interventions":134},[87],[114],[91,116],{"trials":136,"activeCount":96},[],{"intervention":54,"totalTrials":138,"cells":139},24,{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":182,"PHASE4":217,"NA":219},{"trials":141,"activeCount":96},[],{"trials":143,"activeCount":96},[],{"trials":145,"activeCount":96},[146,158,170],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT03847272","A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)","TERMINATED",[85],"2023-10-25","2019-08-01",15,[155],"Patients With Newly Diagnosed Active NISU",[157,54],"prednisone and ustekinumab treatment",{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT03711448","Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis","COMPLETED",[85],"2024-09-11","2019-01-07",38,[167],"Patients Relapsing Refractory Giant Cell Arteritis",[169,157,54],"prednisone treatment",{"nctId":171,"briefTitle":172,"status":149,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT03437746","Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study",[85],"2021-09-30","2021-11-24","2018-03-01",78,[179],"Elective Colorectal Surgery",[181,54],"injection of methylprednisolone at anesthetic induction",{"trials":183,"activeCount":216,"soonestReadout":38},[184,194,206],{"nctId":36,"briefTitle":37,"status":185,"phases":186,"primaryCompletion":38,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"ACTIVE_NOT_RECRUITING",[86],"2027-09","2019-07-02",1200,[191],"Elective Surgery for Any Digestive Cancer",[39,193,54],"Injection of sodium chloride",{"nctId":195,"briefTitle":196,"status":185,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT06037460","TocilizuMab discontinuAtion in GIant Cell Arteritis",[86],"2027-12","2028-11","2024-05-13",120,[203],"Giant Cell Arteritis",[205,54],"Tocilizumab treatment",{"nctId":207,"briefTitle":208,"status":185,"phases":209,"primaryCompletion":77,"completion":77,"start":210,"enrollment":211,"conditions":212,"interventions":213},"NCT03892785","MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial",[86],"2020-01-27",230,[203],[214,205,215,54],"Prednisone treatment","Methotrexate treatment",3,{"trials":218,"activeCount":96},[],{"trials":220,"activeCount":216,"soonestReadout":53},[221,229,239,251,261,272,281,290,297,307,317,327,338,348,358,367,378,388],{"nctId":51,"briefTitle":52,"status":108,"phases":222,"primaryCompletion":53,"completion":53,"start":223,"enrollment":224,"conditions":225,"interventions":227},[],"2018-04-24",200,[226],"Type 1 Diabetes",[54,228],"Urine sample",{"nctId":230,"briefTitle":231,"status":161,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT03512795","Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations",[],"2020-03-05","2018-08-08",71,[237],"HIV-1-infection",[54],{"nctId":240,"briefTitle":241,"status":161,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT06252415","Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With Chromosomal Microarray and Exome Sequencing",[],"2025-07-22","2024-03-27",184,[247],"Congenital Malformation",[249,250],"foetal amniotic fluid sample","blood samples",{"nctId":252,"briefTitle":253,"status":161,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT04126577","Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis",[],"2022-10-27","2019-12-19",27,[259],"Peritonitis",[250],{"nctId":262,"briefTitle":263,"status":161,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT03572556","Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)",[],"2020-03-09","2020-05-03","2018-06-28",60,[270],"Hereditary Hemorrhagic Telangiectasia",[54],{"nctId":273,"briefTitle":274,"status":275,"phases":276,"primaryCompletion":277,"completion":277,"start":277,"enrollment":96,"conditions":278,"interventions":280},"NCT04772092","Impact of Age and Geriatric Co-morbidities on Lymphocyte Phenotype in Patients 70 Years of Age and Older","WITHDRAWN",[],"2021-11",[279],"Geriatrics Immunosenescence",[54],{"nctId":282,"briefTitle":283,"status":161,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":211,"conditions":287,"interventions":289},"NCT03505281","Evaluation of a Functional Lymphocyte Test (QuantiFERON Monitor®) as a Prognostic Marker for Acute Community-acquired Pneumonia",[],"2025-07-30","2018-11-05",[288],"Pneumonia",[54],{"nctId":80,"briefTitle":81,"status":108,"phases":291,"primaryCompletion":77,"completion":77,"start":292,"enrollment":293,"conditions":294,"interventions":296},[88],"2023-08-07",101,[295],"Specific Language and Learning Disorders (SLLD)",[54],{"nctId":298,"briefTitle":299,"status":108,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT05888961","Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials",[88],"2027-07","2023-06-12",72,[305],"Cognitive Disorders",[54],{"nctId":308,"briefTitle":309,"status":161,"phases":310,"primaryCompletion":311,"start":312,"enrollment":313,"conditions":314,"interventions":316},"NCT02820662","Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in New-born Infants",[88],"2018-05-31","2015-07-30",62,[315],"Retinopathy of Prematurity",[54],{"nctId":318,"briefTitle":319,"status":161,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT05708547","Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.",[],"2025-10-16","2023-11-14",61,[325],"Coronary Atherosclerosis",[54],{"nctId":328,"briefTitle":329,"status":330,"phases":331,"primaryCompletion":332,"completion":333,"start":334,"enrollment":268,"conditions":335,"interventions":337},"NCT03313102","Study of T Lymphocytes in Patients With Horton Disease","UNKNOWN",[88],"2023-11","2024-11","2017-11-16",[336],"Horton Disease",[250],{"nctId":339,"briefTitle":340,"status":161,"phases":341,"primaryCompletion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT02851680","Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.",[88],"2015-05","2014-09",476,[346],"Invasive Fungal Infections",[250],{"nctId":349,"briefTitle":350,"status":161,"phases":351,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT02860260","Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke",[88],"2012-01","2011-02",50,[356],"Ischemic Stroke",[54],{"nctId":359,"briefTitle":360,"status":161,"phases":361,"primaryCompletion":362,"completion":362,"start":363,"enrollment":257,"conditions":364,"interventions":366},"NCT02158195","Immunopathology of Autoimmune Hemolytic Anemia",[],"2018-12-27","2013-07-03",[365],"Autoimmune Hemolytic Anemia",[250],{"nctId":368,"briefTitle":369,"status":161,"phases":370,"primaryCompletion":371,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":377},"NCT02814240","Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging",[88],"2015-10-10","2015-03-16",21,[375,376],"Hepatic Steatosis","Pituitary Gland Failure",[54],{"nctId":379,"briefTitle":380,"status":161,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT02857192","Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease",[88],"2019-03-25","2015-10-05",41,[386],"Horton's Disease",[54],{"nctId":389,"briefTitle":390,"status":161,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT03701737","Study of Eating Behaviour and Sense of Taste Before and After Treatment With Nocturnal Continuous Positive Airway Pressure in Overweight Patients With Obstructive Sleep Apnea Syndrome.",[],"2023-01-30","2019-02-25",94,[26,396],"Obstructive Sleep Apnoea Syndrome",[54],{"intervention":399,"totalTrials":216,"cells":400},"BIOLOGICAL ASSESSMENT",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":420,"PHASE4":448,"NA":450},{"trials":402,"activeCount":96},[],{"trials":404,"activeCount":96},[],{"trials":406,"activeCount":92,"soonestReadout":411},[407],{"nctId":408,"briefTitle":409,"status":108,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":303,"conditions":413,"interventions":416},"NCT05089227","Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study",[85],"2028-08","2022-02-03",[414,415,365],"Prolonged Anticoagulation","Venous Thromboembolic Disease",[417,418,419],"treatment \"intervention\"","treatment \"standard\"","biological assessment",{"trials":421,"activeCount":447,"soonestReadout":426},[422,434],{"nctId":423,"briefTitle":424,"status":108,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":431},"NCT06197425","Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer",[86],"2032-05","2026-05-07",1660,[430],"Colon or Upper Rectum Adenocarcinoma",[432,433,399],"\"FOLFIRI\" cures","Trifluridine cures",{"nctId":435,"briefTitle":436,"status":108,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":443},"NCT06813976","PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma",[86],"2033-07","2025-07-02",294,[442],"Ampullary Adenocarcinoma",[444,445,446],"mFOLFORINOX","Capecitabine or gemcitabine","Biological assessment",2,{"trials":449,"activeCount":96},[],{"trials":451,"activeCount":96},[],{"intervention":205,"totalTrials":447,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":470,"NA":472},{"trials":455,"activeCount":96},[],{"trials":457,"activeCount":96},[],{"trials":459,"activeCount":96},[],{"trials":461,"activeCount":447,"soonestReadout":77},[462,466],{"nctId":195,"briefTitle":196,"status":185,"phases":463,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":464,"interventions":465},[86],[203],[205,54],{"nctId":207,"briefTitle":208,"status":185,"phases":467,"primaryCompletion":77,"completion":77,"start":210,"enrollment":211,"conditions":468,"interventions":469},[86],[203],[214,205,215,54],{"trials":471,"activeCount":96},[],{"trials":473,"activeCount":96},[],{"intervention":475,"totalTrials":447,"cells":476},"Biological check-up",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":496,"NA":498},{"trials":478,"activeCount":96},[],{"trials":480,"activeCount":96},[],{"trials":482,"activeCount":96},[],{"trials":484,"activeCount":92,"soonestReadout":411},[485],{"nctId":486,"briefTitle":487,"status":108,"phases":488,"primaryCompletion":411,"completion":411,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT05305794","Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"",[86],"2022-07-12",76,[492],"Double Diabetes",[494,495,475],"Insulin + semaglutide treatment","Usual insulin treatment",{"trials":497,"activeCount":96},[],{"trials":499,"activeCount":92,"soonestReadout":504},[500],{"nctId":501,"briefTitle":502,"status":108,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT06613555","Retinal Microvascularization in OCT-angiography and Systemic Diseases",[],"2044-06","2024-06-19",5000,[508],"Systemic Vascular Damage",[475],{"intervention":169,"totalTrials":447,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":522,"PHASE4":528,"NA":530},{"trials":513,"activeCount":96},[],{"trials":515,"activeCount":96},[],{"trials":517,"activeCount":96},[518],{"nctId":159,"briefTitle":160,"status":161,"phases":519,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":520,"interventions":521},[85],[167],[169,157,54],{"trials":523,"activeCount":92,"soonestReadout":77},[524],{"nctId":207,"briefTitle":208,"status":185,"phases":525,"primaryCompletion":77,"completion":77,"start":210,"enrollment":211,"conditions":526,"interventions":527},[86],[203],[214,205,215,54],{"trials":529,"activeCount":96},[],{"trials":531,"activeCount":96},[],{"intervention":533,"totalTrials":447,"cells":534},"FOLFOX",{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":565,"NA":567},{"trials":536,"activeCount":96},[],{"trials":538,"activeCount":96},[],{"trials":540,"activeCount":96},[],{"trials":542,"activeCount":92,"soonestReadout":559},[543,555],{"nctId":544,"briefTitle":545,"status":330,"phases":546,"primaryCompletion":547,"enrollment":548,"conditions":549,"interventions":552},"NCT02502370","Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma",[86],"2023-09",100,[550,551],"Small Bowel Adenocarcinoma","Adjuvant Chemotherapy for SBA",[553,554,533],"observation alone","LV5FU2",{"nctId":556,"briefTitle":557,"status":108,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT06293625","Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More",[86],"2032-06","2024-06-07",150,[33],[564],"Folfox",{"trials":566,"activeCount":96},[],{"trials":568,"activeCount":96},[],{"intervention":78,"totalTrials":92,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":587,"NA":589},{"trials":572,"activeCount":96},[],{"trials":574,"activeCount":96},[],{"trials":576,"activeCount":96},[],{"trials":578,"activeCount":92,"soonestReadout":77},[579],{"nctId":75,"briefTitle":76,"status":108,"phases":580,"primaryCompletion":77,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":586},[86],"2028-01","2020-01-17",1980,[585],"Patients With Resected Stage II Colon Cancer",[78],{"trials":588,"activeCount":96},[],{"trials":590,"activeCount":96},[],{"intervention":39,"totalTrials":92,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":605,"NA":607},{"trials":594,"activeCount":96},[],{"trials":596,"activeCount":96},[],{"trials":598,"activeCount":96},[],{"trials":600,"activeCount":92,"soonestReadout":38},[601],{"nctId":36,"briefTitle":37,"status":185,"phases":602,"primaryCompletion":38,"completion":187,"start":188,"enrollment":189,"conditions":603,"interventions":604},[86],[191],[39,193,54],{"trials":606,"activeCount":96},[],{"trials":608,"activeCount":96},[],{"intervention":193,"totalTrials":92,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":623,"NA":625},{"trials":612,"activeCount":96},[],{"trials":614,"activeCount":96},[],{"trials":616,"activeCount":96},[],{"trials":618,"activeCount":92,"soonestReadout":38},[619],{"nctId":36,"briefTitle":37,"status":185,"phases":620,"primaryCompletion":38,"completion":187,"start":188,"enrollment":189,"conditions":621,"interventions":622},[86],[191],[39,193,54],{"trials":624,"activeCount":96},[],{"trials":626,"activeCount":96},[],{"intervention":49,"totalTrials":92,"cells":628},{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":635,"PHASE4":646,"NA":648},{"trials":630,"activeCount":96},[],{"trials":632,"activeCount":96},[],{"trials":634,"activeCount":96},[],{"trials":636,"activeCount":92,"soonestReadout":48},[637],{"nctId":46,"briefTitle":47,"status":185,"phases":638,"primaryCompletion":48,"completion":48,"start":639,"enrollment":640,"conditions":641,"interventions":644},[86],"2023-01-02",840,[642,643],"Scheduled Cardiac Surgery With Extracorporeal Circulation","Vasoplegic Syndrome",[49,645],"Norepinephrine",{"trials":647,"activeCount":96},[],{"trials":649,"activeCount":96},[],{"intervention":645,"totalTrials":92,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":664,"NA":666},{"trials":653,"activeCount":96},[],{"trials":655,"activeCount":96},[],{"trials":657,"activeCount":96},[],{"trials":659,"activeCount":92,"soonestReadout":48},[660],{"nctId":46,"briefTitle":47,"status":185,"phases":661,"primaryCompletion":48,"completion":48,"start":639,"enrollment":640,"conditions":662,"interventions":663},[86],[642,643],[49,645],{"trials":665,"activeCount":96},[],{"trials":667,"activeCount":96},[],{"intervention":669,"totalTrials":92,"cells":670},"Dostarlimab",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":690,"NA":692},{"trials":672,"activeCount":96},[],{"trials":674,"activeCount":96},[],{"trials":676,"activeCount":96},[],{"trials":678,"activeCount":92,"soonestReadout":683},[679],{"nctId":680,"briefTitle":681,"status":108,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":688},"NCT06762405","PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients",[86],"2030-09","2025-02-06",68,[687],"Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)\u002F Microsatellite Instability-high (MSI-H)",[669,689],"Biological study on circulating tumor DNA",{"trials":691,"activeCount":96},[],{"trials":693,"activeCount":96},[],{"intervention":689,"totalTrials":92,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":708,"NA":710},{"trials":697,"activeCount":96},[],{"trials":699,"activeCount":96},[],{"trials":701,"activeCount":96},[],{"trials":703,"activeCount":92,"soonestReadout":683},[704],{"nctId":680,"briefTitle":681,"status":108,"phases":705,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":706,"interventions":707},[86],[687],[669,689],{"trials":709,"activeCount":96},[],{"trials":711,"activeCount":96},[],{"intervention":494,"totalTrials":92,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":726,"NA":728},{"trials":715,"activeCount":96},[],{"trials":717,"activeCount":96},[],{"trials":719,"activeCount":96},[],{"trials":721,"activeCount":92,"soonestReadout":411},[722],{"nctId":486,"briefTitle":487,"status":108,"phases":723,"primaryCompletion":411,"completion":411,"start":489,"enrollment":490,"conditions":724,"interventions":725},[86],[492],[494,495,475],{"trials":727,"activeCount":96},[],{"trials":729,"activeCount":96},[],{"intervention":495,"totalTrials":92,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":744,"NA":746},{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":96},[],{"trials":739,"activeCount":92,"soonestReadout":411},[740],{"nctId":486,"briefTitle":487,"status":108,"phases":741,"primaryCompletion":411,"completion":411,"start":489,"enrollment":490,"conditions":742,"interventions":743},[86],[492],[494,495,475],{"trials":745,"activeCount":96},[],{"trials":747,"activeCount":96},[],{"intervention":749,"totalTrials":92,"cells":750},"Argipressin",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":770,"NA":772},{"trials":752,"activeCount":96},[],{"trials":754,"activeCount":96},[],{"trials":756,"activeCount":96},[],{"trials":758,"activeCount":92,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":108,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT07063680","Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock",[86],"2029-01","2026-04-07",390,[767],"Patients With Norepinephrine-refractory Vasoplegic Shock",[749,769],"Chlorure de sodium",{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[],{"intervention":769,"totalTrials":92,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":788,"NA":790},{"trials":777,"activeCount":96},[],{"trials":779,"activeCount":96},[],{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":92,"soonestReadout":763},[784],{"nctId":760,"briefTitle":761,"status":108,"phases":785,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":786,"interventions":787},[86],[767],[749,769],{"trials":789,"activeCount":96},[],{"trials":791,"activeCount":96},[],{"intervention":432,"totalTrials":92,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":806,"NA":808},{"trials":795,"activeCount":96},[],{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":92,"soonestReadout":426},[802],{"nctId":423,"briefTitle":424,"status":108,"phases":803,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":804,"interventions":805},[86],[430],[432,433,399],{"trials":807,"activeCount":96},[],{"trials":809,"activeCount":96},[],{"intervention":433,"totalTrials":92,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":824,"NA":826},{"trials":813,"activeCount":96},[],{"trials":815,"activeCount":96},[],{"trials":817,"activeCount":96},[],{"trials":819,"activeCount":92,"soonestReadout":426},[820],{"nctId":423,"briefTitle":424,"status":108,"phases":821,"primaryCompletion":426,"completion":426,"start":427,"enrollment":428,"conditions":822,"interventions":823},[86],[430],[432,433,399],{"trials":825,"activeCount":96},[],{"trials":827,"activeCount":96},[],{"intervention":829,"totalTrials":92,"cells":830},"Acetylsalicylic acid\u002FAspirin",{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":852,"NA":854},{"trials":832,"activeCount":96},[],{"trials":834,"activeCount":96},[],{"trials":836,"activeCount":96},[],{"trials":838,"activeCount":92,"soonestReadout":844},[839],{"nctId":840,"briefTitle":841,"status":842,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":851},"NCT06774846","Aspirin in Acute Pneumonia in the Elderly: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial.","NOT_YET_RECRUITING",[86],"2029-05","2029-06","2026-02",600,[849,850],"Acute Pneumonia","Elderly Person",[829],{"trials":853,"activeCount":96},[],{"trials":855,"activeCount":96},[],{"intervention":444,"totalTrials":92,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":870,"NA":872},{"trials":859,"activeCount":96},[],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":92,"soonestReadout":438},[866],{"nctId":435,"briefTitle":436,"status":108,"phases":867,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":868,"interventions":869},[86],[442],[444,445,446],{"trials":871,"activeCount":96},[],{"trials":873,"activeCount":96},[],{"intervention":445,"totalTrials":92,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":888,"NA":890},{"trials":877,"activeCount":96},[],{"trials":879,"activeCount":96},[],{"trials":881,"activeCount":96},[],{"trials":883,"activeCount":92,"soonestReadout":438},[884],{"nctId":435,"briefTitle":436,"status":108,"phases":885,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":886,"interventions":887},[86],[442],[444,445,446],{"trials":889,"activeCount":96},[],{"trials":891,"activeCount":96},[],{"intervention":893,"totalTrials":92,"cells":894},"OM-89 [Uro-Vaxom® Capsule]",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":914,"NA":916},{"trials":896,"activeCount":96},[],{"trials":898,"activeCount":96},[],{"trials":900,"activeCount":96},[],{"trials":902,"activeCount":92,"soonestReadout":198},[903],{"nctId":904,"briefTitle":905,"status":108,"phases":906,"primaryCompletion":198,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT06588010","Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder",[86],"2028-12","2024-12-16",110,[911],"Neurogenic Bladder",[893,913],"OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]",{"trials":915,"activeCount":96},[],{"trials":917,"activeCount":96},[],{"intervention":913,"totalTrials":92,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":926,"PHASE4":932,"NA":934},{"trials":921,"activeCount":96},[],{"trials":923,"activeCount":96},[],{"trials":925,"activeCount":96},[],{"trials":927,"activeCount":92,"soonestReadout":198},[928],{"nctId":904,"briefTitle":905,"status":108,"phases":929,"primaryCompletion":198,"completion":907,"start":908,"enrollment":909,"conditions":930,"interventions":931},[86],[911],[893,913],{"trials":933,"activeCount":96},[],{"trials":935,"activeCount":96},[],{"intervention":215,"totalTrials":92,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":950,"NA":952},{"trials":939,"activeCount":96},[],{"trials":941,"activeCount":96},[],{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":92,"soonestReadout":77},[946],{"nctId":207,"briefTitle":208,"status":185,"phases":947,"primaryCompletion":77,"completion":77,"start":210,"enrollment":211,"conditions":948,"interventions":949},[86],[203],[214,205,215,54],{"trials":951,"activeCount":96},[],{"trials":953,"activeCount":96},[],{"intervention":955,"totalTrials":92,"cells":956},"modified FOLFORINOX",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":975,"PHASE4":977,"NA":979},{"trials":958,"activeCount":96},[],{"trials":960,"activeCount":96},[],{"trials":962,"activeCount":92,"soonestReadout":967},[963],{"nctId":964,"briefTitle":965,"status":108,"phases":966,"primaryCompletion":967,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":973},"NCT06278545","Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma",[85],"2027-02","2029-02","2024-02-16",130,[972],"Locally Advanced or Metastatic Small Bowel Adenocarcinoma",[955,974],"Modified FOLFOX",{"trials":976,"activeCount":96},[],{"trials":978,"activeCount":96},[],{"trials":980,"activeCount":96},[],{"intervention":974,"totalTrials":92,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":984,"activeCount":96},[],{"trials":986,"activeCount":96},[],{"trials":988,"activeCount":92,"soonestReadout":967},[989],{"nctId":964,"briefTitle":965,"status":108,"phases":990,"primaryCompletion":967,"completion":968,"start":969,"enrollment":970,"conditions":991,"interventions":992},[85],[972],[955,974],{"trials":994,"activeCount":96},[],{"trials":996,"activeCount":96},[],{"trials":998,"activeCount":96},[],{"intervention":1000,"totalTrials":92,"cells":1001},"FOLFOXIRI Protocol",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1003,"activeCount":96},[],{"trials":1005,"activeCount":96},[],{"trials":1007,"activeCount":92,"soonestReadout":1012},[1008],{"nctId":1009,"briefTitle":1010,"status":108,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1017},"NCT04325425","Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary",[85],"2029-09","2020-09-01",218,[1016],"Neuroendocrine Carcinoma",[1000,1018],"Cisplatin",{"trials":1020,"activeCount":96},[],{"trials":1022,"activeCount":96},[],{"trials":1024,"activeCount":96},[],{"intervention":1018,"totalTrials":92,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1028,"activeCount":96},[],{"trials":1030,"activeCount":96},[],{"trials":1032,"activeCount":92,"soonestReadout":1012},[1033],{"nctId":1009,"briefTitle":1010,"status":108,"phases":1034,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1035,"interventions":1036},[85],[1016],[1000,1018],{"trials":1038,"activeCount":96},[],{"trials":1040,"activeCount":96},[],{"trials":1042,"activeCount":96},[],{"intervention":1044,"totalTrials":92,"cells":1045},"Lithium treatment",{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1047,"activeCount":96},[],{"trials":1049,"activeCount":96},[],{"trials":1051,"activeCount":92,"soonestReadout":1056},[1052],{"nctId":1053,"briefTitle":1054,"status":108,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1061},"NCT06776848","A Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder",[84,85],"2027-09-12","2025-09-12",12,[1060],"Proven Pathogenic or Probably Pathogenic TBR1 Variant",[1044,1062],"biological monitoring",{"trials":1064,"activeCount":96},[],{"trials":1066,"activeCount":96},[],{"trials":1068,"activeCount":96},[],{"intervention":1062,"totalTrials":92,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1072,"activeCount":96},[],{"trials":1074,"activeCount":96},[],{"trials":1076,"activeCount":92,"soonestReadout":1056},[1077],{"nctId":1053,"briefTitle":1054,"status":108,"phases":1078,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1079,"interventions":1080},[84,85],[1060],[1044,1062],{"trials":1082,"activeCount":96},[],{"trials":1084,"activeCount":96},[],{"trials":1086,"activeCount":96},[],{"intervention":1088,"totalTrials":92,"cells":1089},"Alpelisib",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1091,"activeCount":96},[],{"trials":1093,"activeCount":96},[],{"trials":1095,"activeCount":92,"soonestReadout":1100},[1096],{"nctId":1097,"briefTitle":1098,"status":108,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1105},"NCT05577754","Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)",[85],"2027-03","2022-11-28",20,[1104],"Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)",[1088],{"trials":1107,"activeCount":96},[],{"trials":1109,"activeCount":96},[],{"trials":1111,"activeCount":96},[],{"intervention":417,"totalTrials":92,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1115,"activeCount":96},[],{"trials":1117,"activeCount":96},[],{"trials":1119,"activeCount":92,"soonestReadout":411},[1120],{"nctId":408,"briefTitle":409,"status":108,"phases":1121,"primaryCompletion":411,"completion":411,"start":412,"enrollment":303,"conditions":1122,"interventions":1123},[85],[414,415,365],[417,418,419],{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"trials":1129,"activeCount":96},[],{"intervention":418,"totalTrials":92,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1133,"activeCount":96},[],{"trials":1135,"activeCount":96},[],{"trials":1137,"activeCount":92,"soonestReadout":411},[1138],{"nctId":408,"briefTitle":409,"status":108,"phases":1139,"primaryCompletion":411,"completion":411,"start":412,"enrollment":303,"conditions":1140,"interventions":1141},[85],[414,415,365],[417,418,419],{"trials":1143,"activeCount":96},[],{"trials":1145,"activeCount":96},[],{"trials":1147,"activeCount":96},[],{"intervention":1149,"totalTrials":1150,"cells":1151},"Blood sampling",14,{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1160,"NA":1162},{"trials":1153,"activeCount":96},[],{"trials":1155,"activeCount":96},[],{"trials":1157,"activeCount":96},[],{"trials":1159,"activeCount":96},[],{"trials":1161,"activeCount":96},[],{"trials":1163,"activeCount":24,"soonestReadout":1285},[1164,1176,1189,1199,1208,1221,1232,1241,1249,1259,1270,1281,1291,1300],{"nctId":1165,"briefTitle":1166,"status":161,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1175},"NCT04483245","Platelet Activation by a Collagen Analogue in Hemorrhagic Situations",[],"2023-04-11","2021-12-07",83,[1172,1173,1174],"Collagen Analog","Platelet Activation","Hemorrhage",[1149],{"nctId":1177,"briefTitle":1178,"status":161,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1187},"NCT04820959","Validation of New Therapeutic Targets to Prevent Collagen Accumulation During Cardiac Fibrosis: Procollagen C-proteinase Enhancers",[88],"2022-07-07","2020-10-04",66,[1184,1185,1186],"Valvulopathy","Heart Surgery","Procollagen C-Proteinase Enhancers",[1188,1149],"Biopsies",{"nctId":1190,"briefTitle":1191,"status":161,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1198},"NCT06347302","Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment",[88],"2025-10-21","2024-04-25",137,[1197],"Rhegmatogenous Retinal Detachments",[1149],{"nctId":1200,"briefTitle":1201,"status":161,"phases":1202,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":201,"conditions":1205,"interventions":1207},"NCT05315349","Retinal Microvascular Network and Coronary Revascularization Surgery at the Dijon University Hospital",[88],"2025-04-28","2022-06-07",[1206],"Myocardial Revascularization Surgery With Extracorporeal Circulation",[1149],{"nctId":1209,"briefTitle":1210,"status":161,"phases":1211,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1218},"NCT04278300","Study of the Discriminating Power of a Blood Biomarker for Omega-3 Polyunsaturated Fatty Acid Content of the Retina for Age-related Macular Degeneration (AMD)",[],"2020-08-21","2020-09-09","2020-02-11",205,[1217],"Age-related Macular Degeneration",[1219,1220],"blood sampling","faecal sampling",{"nctId":1222,"briefTitle":1223,"status":161,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT05039151","Interstitial Fluid Composition in Patients With Septic Versus Non-septic Shock: an Exploratory Pilot Study",[],"2025-07-19","2021-01-25",26,[1229,23],"Interstitial Liquid",[1231,1219],"interstitial fluid sampling",{"nctId":1233,"briefTitle":1234,"status":108,"phases":1235,"primaryCompletion":1236,"completion":1236,"start":1237,"enrollment":189,"conditions":1238,"interventions":1240},"NCT04417803","Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques",[88],"2046-05","2021-05-17",[1239],"Lymphomas",[1149],{"nctId":1242,"briefTitle":1243,"status":108,"phases":1244,"primaryCompletion":763,"completion":763,"start":1245,"enrollment":561,"conditions":1246,"interventions":1248},"NCT06183632","Lipid Characterisation of Plasma Microparticles in a Large Population of Healthy Donors",[],"2024-01-25",[1247],"Healthy Donor",[1219],{"nctId":1250,"briefTitle":1251,"status":161,"phases":1252,"primaryCompletion":1253,"completion":1253,"start":1254,"enrollment":313,"conditions":1255,"interventions":1258},"NCT02859675","Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease",[],"2021-05-03","2013-10-07",[1256,1257],"Crohn's Disease","Olfactogustatory Perception",[1219],{"nctId":1260,"briefTitle":1261,"status":108,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":224,"conditions":1265,"interventions":1269},"NCT03773159","Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions",[],"2028-05","2019-05-06",[1266,1267,1268],"Von Willebrand Diseases","Major Constitutional Thrombopathy","Patient on Antiplatelet Drugs",[1149],{"nctId":1271,"briefTitle":1272,"status":108,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1280},"NCT07315178","Creation of a Digital Twin for Predicting the Progression of Patients With Chronic Thoracic Aortic Dissection",[88],"2031-11","2025-11-25",400,[1278,1279],"Type A Aortic Dissection With Residual Type B Dissection","Chronic Type B Aortic Dissection",[1219],{"nctId":1282,"briefTitle":1283,"status":108,"phases":1284,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT05099341","DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls",[88],"2027-10","2021-10-01",90,[1289],"Depression",[1149],{"nctId":1292,"briefTitle":1293,"status":161,"phases":1294,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1299},"NCT04860414","Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials.",[88],"2021-06-17","2021-03-03",45,[305],[1149],{"nctId":1301,"briefTitle":1302,"status":108,"phases":1303,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1309},"NCT06692751","The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).",[],"2027-11","2024-11-13",158,[1308],"Microvascular Angina",[1149],{"intervention":73,"totalTrials":1311,"cells":1312},17,{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1346},{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"trials":1318,"activeCount":96},[],{"trials":1320,"activeCount":96},[],{"trials":1322,"activeCount":96},[1323,1335],{"nctId":1324,"briefTitle":1325,"status":149,"phases":1326,"primaryCompletion":1327,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT02721888","Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism",[87],"2019-10-02","2012-07-10",127,[18],[1332,1333,1334],"Liraglutide","MRI\u002F MRS","Blood sample",{"nctId":1336,"briefTitle":1337,"status":161,"phases":1338,"primaryCompletion":1339,"start":1340,"enrollment":490,"conditions":1341,"interventions":1343},"NCT02860299","Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used",[87],"2016-01","2015-02",[1342],"Acute Renal Insufficiency",[1344,1345,73],"citrate 4%","unfractionated heparin",{"trials":1347,"activeCount":216,"soonestReadout":72},[1348,1358,1368,1378,1388,1398,1405,1413,1423,1433,1443,1455,1463,1471,1480],{"nctId":1349,"briefTitle":1350,"status":161,"phases":1351,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":1355,"interventions":1357},"NCT02851602","Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome",[88],"2016-11-14","2013-11-18",89,[1356],"Metabolic Syndrome",[1334],{"nctId":1359,"briefTitle":1360,"status":330,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT02821572","Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)",[],"2024-09","2014-10-02",70,[1366],"Immune Thrombocytopenia",[73],{"nctId":1369,"briefTitle":1370,"status":161,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT02859090","Study of the Expression of Heat Shock Proteins in Populations of B Lymphocytes in Human Tonsils",[88],"2014-11-20","2014-08-26",5,[1376],"Tonsillectomy",[73],{"nctId":1379,"briefTitle":1380,"status":161,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":268,"conditions":1384,"interventions":1386},"NCT02862860","Search for a Link Between the Different Variables for Glycaemia and Oxidative Stress or Impaired HDL Function",[88],"2018-04-17","2012-05-29",[1385],"Type-1 Diabetes",[73,1387],"urine sample",{"nctId":1389,"briefTitle":1390,"status":161,"phases":1391,"primaryCompletion":1392,"enrollment":1393,"conditions":1394,"interventions":1397},"NCT02823132","Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia",[],"2015-06",134,[1395,1396],"Acute Leukemia","Invasive Fungal Infection",[73],{"nctId":1399,"briefTitle":1400,"status":842,"phases":1401,"primaryCompletion":1263,"completion":1263,"start":58,"enrollment":1102,"conditions":1402,"interventions":1404},"NCT07557628","Study of the Hypothalamic Microglial Response as a Function of a Meal's Lipid Content in Humans. A Single-center Prospective Cohort Study in Healthy Male Subjects",[],[1403],"Pathophysiology",[1334],{"nctId":1406,"briefTitle":1407,"status":108,"phases":1408,"primaryCompletion":199,"completion":199,"start":1409,"enrollment":548,"conditions":1410,"interventions":1412},"NCT07174141","Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study",[],"2025-11-28",[1411],"Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)",[1334],{"nctId":1414,"briefTitle":1415,"status":149,"phases":1416,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},"NCT02857556","Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure",[88],"2017-06-30","2014-04-17",10,[1421],"End-stage Chronic Kidney Failure",[1334],{"nctId":1424,"briefTitle":1425,"status":161,"phases":1426,"primaryCompletion":1427,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1432},"NCT02873832","Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS)",[],"2016-04","2015-01",37,[1431],"Myeloproliferative Syndrome",[1334],{"nctId":1434,"briefTitle":1435,"status":161,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1442},"NCT03570060","Stepwise Screening for Silent Atrial Fibrillation After Stroke",[],"2023-03-23","2018-04-01",264,[1441],"Ischemic Cerebrovascular Accident",[1334],{"nctId":1444,"briefTitle":1445,"status":161,"phases":1446,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":1451,"interventions":1453},"NCT03956069","Study of the Diagnostic Value of \"Rapid\" High Throughput Genome Sequencing Analysis in Diagnostic Emergency Situations",[],"2022-01-25","2022-07-25","2020-06-23",57,[1452],"Developmental Anomalies",[73,1454],"genome sequencing",{"nctId":70,"briefTitle":71,"status":108,"phases":1456,"primaryCompletion":72,"completion":72,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1462},[],"2024-06-13",297,[1460,1461],"Neuroendocrine Tumors","MEN1 Mutation",[73],{"nctId":1464,"briefTitle":1465,"status":161,"phases":1466,"primaryCompletion":1467,"enrollment":9,"conditions":1468,"interventions":1470},"NCT02894827","The Effect of When Medication is Taken on Nutritional Status in Hospitalized Patients Older Than 65 Years",[],"2015-09",[1469],"Nutritional Status",[1334],{"nctId":1472,"briefTitle":1473,"status":161,"phases":1474,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1479},"NCT02828670","Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)",[],"2022-02-15","2016-06-07",25,[365],[73],{"nctId":1481,"briefTitle":1482,"status":161,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":440,"conditions":1486,"interventions":1488},"NCT02824107","Psychosocial Risk Factors in Stroke and Myocardial Infarction",[88],"2019-08-26","2016-02-08",[1487,15],"Myocardial Infarction",[73],{"intervention":1490,"totalTrials":216,"cells":1491},"biological samples",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":96},[],{"trials":1495,"activeCount":96},[],{"trials":1497,"activeCount":96},[],{"trials":1499,"activeCount":96},[],{"trials":1501,"activeCount":96},[],{"trials":1503,"activeCount":447,"soonestReadout":58},[1504,1511,1520],{"nctId":56,"briefTitle":57,"status":108,"phases":1505,"primaryCompletion":58,"completion":58,"start":1506,"enrollment":354,"conditions":1507,"interventions":1509},[],"2019-11-14",[1508],"Rare Diseases",[59,1510],"Genetic test",{"nctId":1512,"briefTitle":1513,"status":108,"phases":1514,"primaryCompletion":187,"completion":187,"start":1515,"enrollment":1516,"conditions":1517,"interventions":1519},"NCT06600295","Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action",[],"2024-09-06",306,[1518],"Newly Diagnosed Cancer of the Oropharynx, Oral Cavity, Colon or Liver",[1490],{"nctId":1521,"briefTitle":1522,"status":161,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1529},"NCT01340222","Monocyte Chemotactic Protein-1 (MCP-1) Expressing Monocytes to Predict Preterm Delivery: PhenoMAP Study",[88],"2015-07","2011-03",210,[1528],"Preterm Labour",[1490],{"intervention":228,"totalTrials":216,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1533,"activeCount":96},[],{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":96},[],{"trials":1539,"activeCount":96},[],{"trials":1541,"activeCount":96},[],{"trials":1543,"activeCount":447,"soonestReadout":53},[1544,1548,1552],{"nctId":51,"briefTitle":52,"status":108,"phases":1545,"primaryCompletion":53,"completion":53,"start":223,"enrollment":224,"conditions":1546,"interventions":1547},[],[226],[54,228],{"nctId":1379,"briefTitle":1380,"status":161,"phases":1549,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":268,"conditions":1550,"interventions":1551},[88],[1385],[73,1387],{"nctId":1553,"briefTitle":1554,"status":108,"phases":1555,"primaryCompletion":1304,"completion":1304,"start":1556,"enrollment":1557,"conditions":1558,"interventions":1559},"NCT07564752","The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes",[],"2025-02-25",143,[226],[1560,228],"Blood test",{"intervention":1560,"totalTrials":216,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1564,"activeCount":96},[],{"trials":1566,"activeCount":96},[],{"trials":1568,"activeCount":96},[],{"trials":1570,"activeCount":96},[],{"trials":1572,"activeCount":96},[],{"trials":1574,"activeCount":447,"soonestReadout":1579},[1575,1584,1595],{"nctId":1576,"briefTitle":1577,"status":108,"phases":1578,"primaryCompletion":1579,"completion":1579,"start":1580,"enrollment":1102,"conditions":1581,"interventions":1583},"NCT07110207","Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials",[88],"2027-08","2025-08-18",[1582],"Frontotemporal Lobar Degeneration (FTLD)",[1560],{"nctId":1585,"briefTitle":1586,"status":149,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1593},"NCT05939752","Cardiovascular Complications of Ibrutinib Therapy",[],"2025-08-05","2023-12-20",8,[1592],"Ibrutinib Treatment",[1594],"blood test",{"nctId":1553,"briefTitle":1554,"status":108,"phases":1596,"primaryCompletion":1304,"completion":1304,"start":1556,"enrollment":1557,"conditions":1597,"interventions":1598},[],[226],[1560,228],{"intervention":1510,"totalTrials":92,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1602,"activeCount":96},[],{"trials":1604,"activeCount":96},[],{"trials":1606,"activeCount":96},[],{"trials":1608,"activeCount":96},[],{"trials":1610,"activeCount":96},[],{"trials":1612,"activeCount":92,"soonestReadout":58},[1613],{"nctId":56,"briefTitle":57,"status":108,"phases":1614,"primaryCompletion":58,"completion":58,"start":1506,"enrollment":354,"conditions":1615,"interventions":1616},[],[1508],[59,1510],{"intervention":1618,"totalTrials":92,"cells":1619},"Blood and\u002For tissue sampling",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1621,"activeCount":96},[],{"trials":1623,"activeCount":96},[],{"trials":1625,"activeCount":96},[],{"trials":1627,"activeCount":96},[],{"trials":1629,"activeCount":96},[],{"trials":1631,"activeCount":92,"soonestReadout":1100},[1632],{"nctId":1633,"briefTitle":1634,"status":108,"phases":1635,"primaryCompletion":1100,"completion":198,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1641},"NCT03287193","Identification of the Molecular and\u002For Pathophysiological Bases of Rare Diseases of Genetic Origin (or Rare Forms of Frequent Diseases Suspected of Being of Genetic Origin).",[],"2017-03-13",850,[1639,1640],"Rare Diseases of Genetic Origin","Rare Forms of Common Diseases Suspected of Being Genetic in Origin",[1618,1642],"high-throughput sequencing",{"intervention":1642,"totalTrials":92,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1651,"PHASE4":1653,"NA":1655},{"trials":1646,"activeCount":96},[],{"trials":1648,"activeCount":96},[],{"trials":1650,"activeCount":96},[],{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":92,"soonestReadout":1100},[1657],{"nctId":1633,"briefTitle":1634,"status":108,"phases":1658,"primaryCompletion":1100,"completion":198,"start":1636,"enrollment":1637,"conditions":1659,"interventions":1660},[],[1639,1640],[1618,1642],{"intervention":1662,"totalTrials":92,"cells":1663},"standard biology",{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1665,"activeCount":96},[],{"trials":1667,"activeCount":96},[],{"trials":1669,"activeCount":96},[],{"trials":1671,"activeCount":96},[],{"trials":1673,"activeCount":96},[],{"trials":1675,"activeCount":92,"soonestReadout":1579},[1676],{"nctId":1677,"briefTitle":1678,"status":108,"phases":1679,"primaryCompletion":1579,"completion":1579,"start":1680,"enrollment":970,"conditions":1681,"interventions":1682},"NCT05683873","Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package",[88],"2023-02-13",[356],[1662,1683,1684],"determination of serum GDF-15, osteoprotegerin and ST-2","Ultrasensitive Troponin-Ic",{"intervention":1683,"totalTrials":92,"cells":1686},{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1688,"activeCount":96},[],{"trials":1690,"activeCount":96},[],{"trials":1692,"activeCount":96},[],{"trials":1694,"activeCount":96},[],{"trials":1696,"activeCount":96},[],{"trials":1698,"activeCount":92,"soonestReadout":1579},[1699],{"nctId":1677,"briefTitle":1678,"status":108,"phases":1700,"primaryCompletion":1579,"completion":1579,"start":1680,"enrollment":970,"conditions":1701,"interventions":1702},[88],[356],[1662,1683,1684],{"intervention":1684,"totalTrials":92,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1713,"NA":1715},{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[],{"trials":1710,"activeCount":96},[],{"trials":1712,"activeCount":96},[],{"trials":1714,"activeCount":96},[],{"trials":1716,"activeCount":92,"soonestReadout":1579},[1717],{"nctId":1677,"briefTitle":1678,"status":108,"phases":1718,"primaryCompletion":1579,"completion":1579,"start":1680,"enrollment":970,"conditions":1719,"interventions":1720},[88],[356],[1662,1683,1684],{"intervention":1722,"totalTrials":92,"cells":1723},"Additional blood samples",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1725,"activeCount":96},[],{"trials":1727,"activeCount":96},[],{"trials":1729,"activeCount":96},[],{"trials":1731,"activeCount":96},[],{"trials":1733,"activeCount":96},[],{"trials":1735,"activeCount":92,"soonestReadout":1285},[1736],{"nctId":1737,"briefTitle":1738,"status":108,"phases":1739,"primaryCompletion":1285,"completion":1285,"start":1740,"enrollment":177,"conditions":1741,"interventions":1744},"NCT06609668","Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)",[],"2024-10-10",[1742,1743],"Giant Cell Arteritis (GCA)","Polymyalgia Rheumatica (PMR)",[1722],{"intervention":1746,"totalTrials":92,"cells":1747},"Collection of tube bottoms from blood samples taken in the clinic",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1749,"activeCount":96},[],{"trials":1751,"activeCount":96},[],{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":92,"soonestReadout":1764},[1760],{"nctId":1761,"briefTitle":1762,"status":108,"phases":1763,"primaryCompletion":1764,"completion":1764,"start":1765,"enrollment":1276,"conditions":1766,"interventions":1768},"NCT06905106","POlycythemia, Proteins and ErYthropoiesis",[],"2028-09","2024-09-01",[1767],"Erythropoiesis",[1746],{"intervention":1770,"totalTrials":92,"cells":1771},"blood sampling for high molecular weight DNA extraction",{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1773,"activeCount":96},[],{"trials":1775,"activeCount":96},[],{"trials":1777,"activeCount":96},[],{"trials":1779,"activeCount":96},[],{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":92,"soonestReadout":1788},[1784],{"nctId":1785,"briefTitle":1786,"status":108,"phases":1787,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1526,"conditions":1790,"interventions":1792},"NCT06467175","The Benefits of Long-read High-throughput Genomic Sequencing for the Causal Diagnosis of Cerebellar Ataxias",[88],"2028-06","2024-12-11",[1791],"Cerebellar Ataxias",[1770],{"intervention":1794,"totalTrials":92,"cells":1795},"Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[],{"trials":1805,"activeCount":96},[],{"trials":1807,"activeCount":92,"soonestReadout":1788},[1808],{"nctId":1809,"briefTitle":1810,"status":108,"phases":1811,"primaryCompletion":1788,"completion":1788,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1816},"NCT05449119","Loss of Autonomy in the Elderly: Relationships Between Gut Microbiota Diversity, Nutrition and Cognitive and Sensory-motor Disturbances in \"Small Eaters\" and \"Non Small Eaters\"",[],"2023-06-13",140,[1815],"Elderly Small Eater",[1794],{"intervention":63,"totalTrials":92,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1820,"activeCount":96},[],{"trials":1822,"activeCount":96},[],{"trials":1824,"activeCount":96},[],{"trials":1826,"activeCount":96},[],{"trials":1828,"activeCount":96},[],{"trials":1830,"activeCount":92,"soonestReadout":58},[1831],{"nctId":61,"briefTitle":62,"status":108,"phases":1832,"primaryCompletion":58,"completion":58,"start":1833,"enrollment":1182,"conditions":1834,"interventions":1836},[88],"2024-05-27",[1835],"Idiopathic Parkinson's Disease and Lewy Body Disease",[63],{"intervention":68,"totalTrials":92,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1847,"NA":1849},{"trials":1840,"activeCount":96},[],{"trials":1842,"activeCount":96},[],{"trials":1844,"activeCount":96},[],{"trials":1846,"activeCount":96},[],{"trials":1848,"activeCount":96},[],{"trials":1850,"activeCount":92,"soonestReadout":67},[1851],{"nctId":65,"briefTitle":66,"status":108,"phases":1852,"primaryCompletion":67,"completion":1853,"start":1854,"enrollment":506,"conditions":1855,"interventions":1857},[],"2031-07","2025-05-05",[1856],"Newborn Screening Programmes for Rare Diseases",[68],{"intervention":44,"totalTrials":92,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1866,"PHASE4":1868,"NA":1870},{"trials":1861,"activeCount":96},[],{"trials":1863,"activeCount":96},[],{"trials":1865,"activeCount":96},[],{"trials":1867,"activeCount":96},[],{"trials":1869,"activeCount":96},[],{"trials":1871,"activeCount":92,"soonestReadout":43},[1872],{"nctId":41,"briefTitle":42,"status":108,"phases":1873,"primaryCompletion":43,"completion":43,"start":1874,"enrollment":548,"conditions":1875,"interventions":1877},[],"2025-01-21",[1876],"Hemostasis",[44],{"intervention":1879,"totalTrials":92,"cells":1880},"Blood sample +\u002F- skin biopsy",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1882,"activeCount":96},[],{"trials":1884,"activeCount":96},[],{"trials":1886,"activeCount":96},[],{"trials":1888,"activeCount":96},[],{"trials":1890,"activeCount":96},[],{"trials":1892,"activeCount":92,"soonestReadout":1897},[1893],{"nctId":1894,"briefTitle":1895,"status":108,"phases":1896,"primaryCompletion":1897,"completion":1897,"start":1898,"enrollment":1899,"conditions":1900,"interventions":1902},"NCT05448326","The Diagnostic Observatory: Combating Diagnostic Wandering and Impasse Within the AnDDI-Rares Network",[],"2029-03","2022-03-28",1280,[1901],"Developmental Abnormality",[1879],{"intervention":1904,"totalTrials":92,"cells":1905},"Maternal blood sampling",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1907,"activeCount":96},[],{"trials":1909,"activeCount":96},[],{"trials":1911,"activeCount":96},[],{"trials":1913,"activeCount":96},[],{"trials":1915,"activeCount":96},[],{"trials":1917,"activeCount":92,"soonestReadout":967},[1918],{"nctId":1919,"briefTitle":1920,"status":108,"phases":1921,"primaryCompletion":967,"completion":967,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1927},"NCT04819893","Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.",[],"2021-04-20",135,[1925,1926],"Prematurity","Retinopathy",[1904,1928,1929],"Umbilical cord blood sampling","Placenta sampling",{"intervention":1928,"totalTrials":92,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1933,"activeCount":96},[],{"trials":1935,"activeCount":96},[],{"trials":1937,"activeCount":96},[],{"trials":1939,"activeCount":96},[],{"trials":1941,"activeCount":96},[],{"trials":1943,"activeCount":92,"soonestReadout":967},[1944],{"nctId":1919,"briefTitle":1920,"status":108,"phases":1945,"primaryCompletion":967,"completion":967,"start":1922,"enrollment":1923,"conditions":1946,"interventions":1947},[],[1925,1926],[1904,1928,1929],{"intervention":1929,"totalTrials":92,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1958,"NA":1960},{"trials":1951,"activeCount":96},[],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[],{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":92,"soonestReadout":967},[1962],{"nctId":1919,"briefTitle":1920,"status":108,"phases":1963,"primaryCompletion":967,"completion":967,"start":1922,"enrollment":1923,"conditions":1964,"interventions":1965},[],[1925,1926],[1904,1928,1929],{"intervention":1967,"totalTrials":447,"cells":1968},"Citrate 4%",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1988,"NA":1994},{"trials":1970,"activeCount":96},[],{"trials":1972,"activeCount":96},[],{"trials":1974,"activeCount":96},[],{"trials":1976,"activeCount":96},[1977],{"nctId":1978,"briefTitle":1979,"status":161,"phases":1980,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":1984,"conditions":1985,"interventions":1987},"NCT01962116","Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU",[86],"2016-04-01","2016-12-31","2013-06-14",405,[1986],"Patients With Acute Renal Insufficiency",[1967,1345],{"trials":1989,"activeCount":96},[1990],{"nctId":1336,"briefTitle":1337,"status":161,"phases":1991,"primaryCompletion":1339,"start":1340,"enrollment":490,"conditions":1992,"interventions":1993},[87],[1342],[1344,1345,73],{"trials":1995,"activeCount":96},[],{"intervention":1345,"totalTrials":447,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2004,"PHASE4":2010,"NA":2016},{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[],{"trials":2003,"activeCount":96},[],{"trials":2005,"activeCount":96},[2006],{"nctId":1978,"briefTitle":1979,"status":161,"phases":2007,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":1984,"conditions":2008,"interventions":2009},[86],[1986],[1967,1345],{"trials":2011,"activeCount":96},[2012],{"nctId":1336,"briefTitle":1337,"status":161,"phases":2013,"primaryCompletion":1339,"start":1340,"enrollment":490,"conditions":2014,"interventions":2015},[87],[1342],[1344,1345,73],{"trials":2017,"activeCount":96},[],{"intervention":2019,"totalTrials":92,"cells":2020},"Ropivacaine",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2040},{"trials":2022,"activeCount":96},[],{"trials":2024,"activeCount":96},[],{"trials":2026,"activeCount":96},[],{"trials":2028,"activeCount":96},[],{"trials":2030,"activeCount":96},[2031],{"nctId":2032,"briefTitle":2033,"status":161,"phases":2034,"primaryCompletion":2035,"completion":2035,"start":2036,"enrollment":354,"conditions":2037,"interventions":2039},"NCT03657979","TAP-Block in Abdominal Aortic Surgery",[87],"2012-08-29","2011-09-05",[2038],"Aortic Aneurysm, Abdominal",[2019],{"trials":2041,"activeCount":96},[],{"intervention":1333,"totalTrials":92,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2058},{"trials":2045,"activeCount":96},[],{"trials":2047,"activeCount":96},[],{"trials":2049,"activeCount":96},[],{"trials":2051,"activeCount":96},[],{"trials":2053,"activeCount":96},[2054],{"nctId":1324,"briefTitle":1325,"status":149,"phases":2055,"primaryCompletion":1327,"start":1328,"enrollment":1329,"conditions":2056,"interventions":2057},[87],[18],[1332,1333,1334],{"trials":2059,"activeCount":96},[],{"intervention":2061,"totalTrials":92,"cells":2062},"maintenance of anaesthesia with propofol",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2085},{"trials":2064,"activeCount":96},[],{"trials":2066,"activeCount":96},[],{"trials":2068,"activeCount":96},[],{"trials":2070,"activeCount":96},[],{"trials":2072,"activeCount":96},[2073],{"nctId":2074,"briefTitle":2075,"status":161,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2083},"NCT03215446","Evaluate the Muscle Protection Effect of Sevoflurane Sedation in Vascular Surgery",[87],"2018-05-29","2018-10-19","2016-06-13",164,[2082],"Vascular Surgery",[2061,2084],"maintenance of anaesthesia with sevoflurane",{"trials":2086,"activeCount":96},[],{"intervention":2084,"totalTrials":92,"cells":2088},{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2097,"NA":2103},{"trials":2090,"activeCount":96},[],{"trials":2092,"activeCount":96},[],{"trials":2094,"activeCount":96},[],{"trials":2096,"activeCount":96},[],{"trials":2098,"activeCount":96},[2099],{"nctId":2074,"briefTitle":2075,"status":161,"phases":2100,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":2080,"conditions":2101,"interventions":2102},[87],[2082],[2061,2084],{"trials":2104,"activeCount":96},[],{"intervention":2106,"totalTrials":92,"cells":2107},"SSRI",{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2114,"PHASE4":2116,"NA":2126},{"trials":2109,"activeCount":96},[],{"trials":2111,"activeCount":96},[],{"trials":2113,"activeCount":96},[],{"trials":2115,"activeCount":96},[],{"trials":2117,"activeCount":96},[2118],{"nctId":2119,"briefTitle":2120,"status":149,"phases":2121,"primaryCompletion":2122,"start":2123,"enrollment":1419,"conditions":2124,"interventions":2125},"NCT02042573","Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression",[87],"2018-06-05","2013-11-25",[1289],[2106],{"trials":2127,"activeCount":96},[],{"intervention":2129,"totalTrials":92,"cells":2130},"Rosuvastatin",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2150},{"trials":2132,"activeCount":96},[],{"trials":2134,"activeCount":96},[],{"trials":2136,"activeCount":96},[],{"trials":2138,"activeCount":96},[],{"trials":2140,"activeCount":96},[2141],{"nctId":2142,"briefTitle":2143,"status":161,"phases":2144,"primaryCompletion":2145,"completion":2146,"start":2147,"enrollment":1590,"conditions":2148,"interventions":2149},"NCT00658463","Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients",[87],"2007-06","2007-09","2006-01",[21],[2129],{"trials":2151,"activeCount":96},[],{"intervention":2153,"totalTrials":92,"cells":2154},"2 different procedures of administration of insulin",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2163,"NA":2172},{"trials":2156,"activeCount":96},[],{"trials":2158,"activeCount":96},[],{"trials":2160,"activeCount":96},[],{"trials":2162,"activeCount":96},[],{"trials":2164,"activeCount":96},[2165],{"nctId":2166,"briefTitle":2167,"status":330,"phases":2168,"primaryCompletion":2169,"completion":1467,"start":352,"enrollment":268,"conditions":2170,"interventions":2171},"NCT01889914","TReatment by Insulin Continuous Infusion in Type 2 DIAbetes",[87],"2015-03",[21],[2153],{"trials":2173,"activeCount":96},[],{"intervention":2175,"totalTrials":92,"cells":2176},"Ropivacaine 0.2%",{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2181,"PHASE3":2183,"PHASE4":2185,"NA":2198},{"trials":2178,"activeCount":96},[],{"trials":2180,"activeCount":96},[],{"trials":2182,"activeCount":96},[],{"trials":2184,"activeCount":96},[],{"trials":2186,"activeCount":96},[2187],{"nctId":2188,"briefTitle":2189,"status":161,"phases":2190,"primaryCompletion":2191,"start":2192,"enrollment":2193,"conditions":2194,"interventions":2196},"NCT02055664","The Tap Block Technique Via the Anterior Approach in Elective Surgery of the Spine",[87],"2015-08-12","2014-01-23",80,[2195],"Elective Surgery of the Spine by Laparotomy",[2175,2197],"Chlorure de sodium 0.9%",{"trials":2199,"activeCount":96},[],{"intervention":2197,"totalTrials":92,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2216},{"trials":2203,"activeCount":96},[],{"trials":2205,"activeCount":96},[],{"trials":2207,"activeCount":96},[],{"trials":2209,"activeCount":96},[],{"trials":2211,"activeCount":96},[2212],{"nctId":2188,"briefTitle":2189,"status":161,"phases":2213,"primaryCompletion":2191,"start":2192,"enrollment":2193,"conditions":2214,"interventions":2215},[87],[2195],[2175,2197],{"trials":2217,"activeCount":96},[],{"intervention":2219,"totalTrials":92,"cells":2220},"collection of biological data",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2242},{"trials":2222,"activeCount":96},[],{"trials":2224,"activeCount":96},[],{"trials":2226,"activeCount":96},[],{"trials":2228,"activeCount":96},[],{"trials":2230,"activeCount":96},[2231],{"nctId":2232,"briefTitle":2233,"status":161,"phases":2234,"primaryCompletion":2235,"completion":2235,"start":2236,"enrollment":2237,"conditions":2238,"interventions":2241},"NCT05032521","Treatment of Hyperlactatemia in Acute Circulatory Failure Based on Analysis of CO2: a Prospective Randomized Superiority Study (The LACTEL Study)",[87],"2023-11-30","2021-11-02",180,[2239,2240],"Hyperlactatemia","Actue Circulatory Failure",[2219],{"trials":2243,"activeCount":96},[],{"intervention":2245,"totalTrials":92,"cells":2246},"pioglitazone",{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2255,"NA":2267},{"trials":2248,"activeCount":96},[],{"trials":2250,"activeCount":96},[],{"trials":2252,"activeCount":96},[],{"trials":2254,"activeCount":96},[],{"trials":2256,"activeCount":96},[2257],{"nctId":2258,"briefTitle":2259,"status":161,"phases":2260,"primaryCompletion":2261,"completion":2261,"start":2262,"enrollment":2263,"conditions":2264,"interventions":2265},"NCT00953498","Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins",[87],"2012-03","2007-10",40,[18],[2245,2266],"rosiglitazone",{"trials":2268,"activeCount":96},[],{"intervention":2266,"totalTrials":92,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2285},{"trials":2272,"activeCount":96},[],{"trials":2274,"activeCount":96},[],{"trials":2276,"activeCount":96},[],{"trials":2278,"activeCount":96},[],{"trials":2280,"activeCount":96},[2281],{"nctId":2258,"briefTitle":2259,"status":161,"phases":2282,"primaryCompletion":2261,"completion":2261,"start":2262,"enrollment":2263,"conditions":2283,"interventions":2284},[87],[18],[2245,2266],{"trials":2286,"activeCount":96},[],{"intervention":2288,"totalTrials":92,"cells":2289},"Levobupivacaine",{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2314},{"trials":2291,"activeCount":96},[],{"trials":2293,"activeCount":96},[],{"trials":2295,"activeCount":96},[],{"trials":2297,"activeCount":96},[],{"trials":2299,"activeCount":96},[2300],{"nctId":2301,"briefTitle":2302,"status":161,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2311},"NCT02851394","Advantage of Tramadol in Local Analgesia Post-Sternotomy",[87],"2016-05","2016-10","2015-10",160,[2309,2310],"Heart Surgery Via Sternotomy","Post-operative Analgesia",[2288,2312,2313],"levobupivacaine","tramadol",{"trials":2315,"activeCount":96},[],{"intervention":2313,"totalTrials":92,"cells":2317},{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2324,"PHASE4":2326,"NA":2332},{"trials":2319,"activeCount":96},[],{"trials":2321,"activeCount":96},[],{"trials":2323,"activeCount":96},[],{"trials":2325,"activeCount":96},[],{"trials":2327,"activeCount":96},[2328],{"nctId":2301,"briefTitle":2302,"status":161,"phases":2329,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2330,"interventions":2331},[87],[2309,2310],[2288,2312,2313],{"trials":2333,"activeCount":96},[],{"intervention":2335,"totalTrials":92,"cells":2336},"Ropivacaine 500mg\u002F100ml Naropeine",{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2357},{"trials":2338,"activeCount":96},[],{"trials":2340,"activeCount":96},[],{"trials":2342,"activeCount":96},[],{"trials":2344,"activeCount":96},[],{"trials":2346,"activeCount":96},[2347],{"nctId":2348,"briefTitle":2349,"status":161,"phases":2350,"primaryCompletion":2351,"completion":2351,"start":2352,"enrollment":354,"conditions":2353,"interventions":2355},"NCT02080728","Transversus Abdominis Plane Block During Kidney Transplant Surgery",[87],"2014-07-09","2013-07-23",[2354],"Kidney Transplant",[2335,2356],"0.9% sodium chloride BAXTER",{"trials":2358,"activeCount":96},[],{"intervention":2356,"totalTrials":92,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2375},{"trials":2362,"activeCount":96},[],{"trials":2364,"activeCount":96},[],{"trials":2366,"activeCount":96},[],{"trials":2368,"activeCount":96},[],{"trials":2370,"activeCount":96},[2371],{"nctId":2348,"briefTitle":2349,"status":161,"phases":2372,"primaryCompletion":2351,"completion":2351,"start":2352,"enrollment":354,"conditions":2373,"interventions":2374},[87],[2354],[2335,2356],{"trials":2376,"activeCount":96},[],{"intervention":2378,"totalTrials":92,"cells":2379},"LEVEMIR",{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2388,"NA":2400},{"trials":2381,"activeCount":96},[],{"trials":2383,"activeCount":96},[],{"trials":2385,"activeCount":96},[],{"trials":2387,"activeCount":96},[],{"trials":2389,"activeCount":96},[2390],{"nctId":2391,"briefTitle":2392,"status":149,"phases":2393,"primaryCompletion":2394,"start":2395,"enrollment":1150,"conditions":2396,"interventions":2398},"NCT02048189","Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes",[87],"2015-02-26","2012-03-08",[2397],"Patient With Type 2 Diabetes Treated With Insulin Using a Baseline\u002FBolus Strategy",[2378,2399],"APIDRA",{"trials":2401,"activeCount":96},[],{"intervention":2399,"totalTrials":92,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2418},{"trials":2405,"activeCount":96},[],{"trials":2407,"activeCount":96},[],{"trials":2409,"activeCount":96},[],{"trials":2411,"activeCount":96},[],{"trials":2413,"activeCount":96},[2414],{"nctId":2391,"briefTitle":2392,"status":149,"phases":2415,"primaryCompletion":2394,"start":2395,"enrollment":1150,"conditions":2416,"interventions":2417},[87],[2397],[2378,2399],{"trials":2419,"activeCount":96},[],{"intervention":2421,"totalTrials":92,"cells":2422},"total anaesthesia and postoperative inhaled sedation with Sevoflurane",{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2429,"PHASE4":2431,"NA":2445},{"trials":2424,"activeCount":96},[],{"trials":2426,"activeCount":96},[],{"trials":2428,"activeCount":96},[],{"trials":2430,"activeCount":96},[],{"trials":2432,"activeCount":96},[2433],{"nctId":2434,"briefTitle":2435,"status":161,"phases":2436,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":2441,"interventions":2443},"NCT02851433","Evaluate the Protective Effect of Conditioning With Sevoflurane on the Myocardium",[87],"2017-08-29","2017-09-04","2015-10-14",82,[2442],"Cardiac Surgery",[2421,2444],"total intravenous anaesthesia with Propofol.",{"trials":2446,"activeCount":96},[],{"intervention":2444,"totalTrials":92,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2457,"NA":2463},{"trials":2450,"activeCount":96},[],{"trials":2452,"activeCount":96},[],{"trials":2454,"activeCount":96},[],{"trials":2456,"activeCount":96},[],{"trials":2458,"activeCount":96},[2459],{"nctId":2434,"briefTitle":2435,"status":161,"phases":2460,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":2461,"interventions":2462},[87],[2442],[2421,2444],{"trials":2464,"activeCount":96},[],{"intervention":2466,"totalTrials":92,"cells":2467},"Dapagliflozin",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2490},{"trials":2469,"activeCount":96},[],{"trials":2471,"activeCount":96},[],{"trials":2473,"activeCount":96},[],{"trials":2475,"activeCount":96},[],{"trials":2477,"activeCount":96},[2478],{"nctId":2479,"briefTitle":2480,"status":161,"phases":2481,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":2484,"conditions":2485,"interventions":2488},"NCT03269058","Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes",[87],"2021-05-06","2017-12-20",28,[2486,2487],"Type-2 Diabetes","Oral Antidiabetics",[2466,2489],"Placebos",{"trials":2491,"activeCount":96},[],{"intervention":2489,"totalTrials":92,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2502,"NA":2508},{"trials":2495,"activeCount":96},[],{"trials":2497,"activeCount":96},[],{"trials":2499,"activeCount":96},[],{"trials":2501,"activeCount":96},[],{"trials":2503,"activeCount":96},[2504],{"nctId":2479,"briefTitle":2480,"status":161,"phases":2505,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":2484,"conditions":2506,"interventions":2507},[87],[2486,2487],[2466,2489],{"trials":2509,"activeCount":96},[],{"intervention":2511,"totalTrials":92,"cells":2512},"Aflibercept Injection [Eylea]",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2532,"NA":2534},{"trials":2514,"activeCount":96},[],{"trials":2516,"activeCount":96},[],{"trials":2518,"activeCount":96},[],{"trials":2520,"activeCount":96},[2521],{"nctId":2522,"briefTitle":2523,"status":149,"phases":2524,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2530},"NCT03845049","Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1",[86],"2025-03-26","2019-07-03",16,[2529],"Macular Telangiectasia",[2511,2531],"SHAM",{"trials":2533,"activeCount":96},[],{"trials":2535,"activeCount":96},[],{"intervention":2531,"totalTrials":92,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2544,"PHASE4":2550,"NA":2552},{"trials":2539,"activeCount":96},[],{"trials":2541,"activeCount":96},[],{"trials":2543,"activeCount":96},[],{"trials":2545,"activeCount":96},[2546],{"nctId":2522,"briefTitle":2523,"status":149,"phases":2547,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":2527,"conditions":2548,"interventions":2549},[86],[2529],[2511,2531],{"trials":2551,"activeCount":96},[],{"trials":2553,"activeCount":96},[],{"intervention":2555,"totalTrials":92,"cells":2556},"Botulinum toxin",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2574,"NA":2576},{"trials":2558,"activeCount":96},[],{"trials":2560,"activeCount":96},[],{"trials":2562,"activeCount":96},[],{"trials":2564,"activeCount":96},[2565],{"nctId":2566,"briefTitle":2567,"status":149,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":92,"conditions":2571,"interventions":2573},"NCT04722809","Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology",[86],"2022-08-31","2022-05-25",[2572],"Bruxism",[2555],{"trials":2575,"activeCount":96},[],{"trials":2577,"activeCount":96},[],{"intervention":2579,"totalTrials":92,"cells":2580},"Sorafenib + Pravastatin",{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2587,"PHASE4":2600,"NA":2602},{"trials":2582,"activeCount":96},[],{"trials":2584,"activeCount":96},[],{"trials":2586,"activeCount":96},[],{"trials":2588,"activeCount":96},[2589],{"nctId":2590,"briefTitle":2591,"status":161,"phases":2592,"primaryCompletion":2593,"start":2594,"enrollment":2595,"conditions":2596,"interventions":2598},"NCT01903694","Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma",[86],"2013-11","2010-03",474,[2597],"Child-Pugh A Hepatocellular Carcinoma",[2579,2599],"Sorafenib",{"trials":2601,"activeCount":96},[],{"trials":2603,"activeCount":96},[],{"intervention":2599,"totalTrials":92,"cells":2605},{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2612,"PHASE4":2618,"NA":2620},{"trials":2607,"activeCount":96},[],{"trials":2609,"activeCount":96},[],{"trials":2611,"activeCount":96},[],{"trials":2613,"activeCount":96},[2614],{"nctId":2590,"briefTitle":2591,"status":161,"phases":2615,"primaryCompletion":2593,"start":2594,"enrollment":2595,"conditions":2616,"interventions":2617},[86],[2597],[2579,2599],{"trials":2619,"activeCount":96},[],{"trials":2621,"activeCount":96},[],{"intervention":2623,"totalTrials":92,"cells":2624},"Dexmedetomidine 100 Mcg\u002FmL Intravenous Solution",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2631,"PHASE4":2645,"NA":2647},{"trials":2626,"activeCount":96},[],{"trials":2628,"activeCount":96},[],{"trials":2630,"activeCount":96},[],{"trials":2632,"activeCount":96},[2633],{"nctId":2634,"briefTitle":2635,"status":149,"phases":2636,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2643},"NCT03953677","Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock",[86],"2023-01-31","2023-03-22","2019-10-27",32,[23,2642],"Vasopressor Resistance",[2623,2644],"5% glucose Infusion solution",{"trials":2646,"activeCount":96},[],{"trials":2648,"activeCount":96},[],{"intervention":2644,"totalTrials":92,"cells":2650},{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2663,"NA":2665},{"trials":2652,"activeCount":96},[],{"trials":2654,"activeCount":96},[],{"trials":2656,"activeCount":96},[],{"trials":2658,"activeCount":96},[2659],{"nctId":2634,"briefTitle":2635,"status":149,"phases":2660,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2661,"interventions":2662},[86],[23,2642],[2623,2644],{"trials":2664,"activeCount":96},[],{"trials":2666,"activeCount":96},[],{"intervention":2668,"totalTrials":92,"cells":2669},"BEACOPPesc",{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2687,"NA":2689},{"trials":2671,"activeCount":96},[],{"trials":2673,"activeCount":96},[],{"trials":2675,"activeCount":96},[],{"trials":2677,"activeCount":96},[2678],{"nctId":2679,"briefTitle":2680,"status":161,"phases":2681,"start":2682,"conditions":2683,"interventions":2685},"NCT01358747","Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL",[86],"2011-05",[2684],"Hodgkin's Lymphoma",[2668,2686],"BEACOPPesc - ABVD - PET2",{"trials":2688,"activeCount":96},[],{"trials":2690,"activeCount":96},[],{"intervention":2686,"totalTrials":92,"cells":2692},{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2697,"PHASE3":2699,"PHASE4":2705,"NA":2707},{"trials":2694,"activeCount":96},[],{"trials":2696,"activeCount":96},[],{"trials":2698,"activeCount":96},[],{"trials":2700,"activeCount":96},[2701],{"nctId":2679,"briefTitle":2680,"status":161,"phases":2702,"start":2682,"conditions":2703,"interventions":2704},[86],[2684],[2668,2686],{"trials":2706,"activeCount":96},[],{"trials":2708,"activeCount":96},[],{"intervention":553,"totalTrials":92,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2723,"NA":2725},{"trials":2712,"activeCount":96},[],{"trials":2714,"activeCount":96},[],{"trials":2716,"activeCount":96},[],{"trials":2718,"activeCount":96},[2719],{"nctId":544,"briefTitle":545,"status":330,"phases":2720,"primaryCompletion":547,"enrollment":548,"conditions":2721,"interventions":2722},[86],[550,551],[553,554,533],{"trials":2724,"activeCount":96},[],{"trials":2726,"activeCount":96},[],{"intervention":554,"totalTrials":92,"cells":2728},{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2733,"PHASE3":2735,"PHASE4":2741,"NA":2743},{"trials":2730,"activeCount":96},[],{"trials":2732,"activeCount":96},[],{"trials":2734,"activeCount":96},[],{"trials":2736,"activeCount":96},[2737],{"nctId":544,"briefTitle":545,"status":330,"phases":2738,"primaryCompletion":547,"enrollment":548,"conditions":2739,"interventions":2740},[86],[550,551],[553,554,533],{"trials":2742,"activeCount":96},[],{"trials":2744,"activeCount":96},[],{"intervention":2746,"totalTrials":92,"cells":2747},"Levosimendan",{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2754,"PHASE4":2766,"NA":2768},{"trials":2749,"activeCount":96},[],{"trials":2751,"activeCount":96},[],{"trials":2753,"activeCount":96},[],{"trials":2755,"activeCount":96},[2756],{"nctId":2757,"briefTitle":2758,"status":149,"phases":2759,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":2440,"conditions":2762,"interventions":2764},"NCT04158674","Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS",[86],"2023-10-11","2020-02-24",[2763],"Acute Decompensated Heart Failure",[2746,2765],"Cernevit",{"trials":2767,"activeCount":96},[],{"trials":2769,"activeCount":96},[],{"intervention":2765,"totalTrials":92,"cells":2771},{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2778,"PHASE4":2784,"NA":2786},{"trials":2773,"activeCount":96},[],{"trials":2775,"activeCount":96},[],{"trials":2777,"activeCount":96},[],{"trials":2779,"activeCount":96},[2780],{"nctId":2757,"briefTitle":2758,"status":149,"phases":2781,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":2440,"conditions":2782,"interventions":2783},[86],[2763],[2746,2765],{"trials":2785,"activeCount":96},[],{"trials":2787,"activeCount":96},[],{"intervention":2789,"totalTrials":92,"cells":2790},"Fluoropyrimidine",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2797,"PHASE4":2807,"NA":2809},{"trials":2792,"activeCount":96},[],{"trials":2794,"activeCount":96},[],{"trials":2796,"activeCount":96},[],{"trials":2798,"activeCount":96},[2799],{"nctId":2800,"briefTitle":2801,"status":330,"phases":2802,"primaryCompletion":547,"completion":43,"start":210,"enrollment":1276,"conditions":2803,"interventions":2805},"NCT04188145","A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer",[86],[2804],"Metastatic Colorectal Cancer",[2789,2806],"Bevacizumab",{"trials":2808,"activeCount":96},[],{"trials":2810,"activeCount":96},[],{"intervention":2806,"totalTrials":92,"cells":2812},{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2825,"NA":2827},{"trials":2814,"activeCount":96},[],{"trials":2816,"activeCount":96},[],{"trials":2818,"activeCount":96},[],{"trials":2820,"activeCount":96},[2821],{"nctId":2800,"briefTitle":2801,"status":330,"phases":2822,"primaryCompletion":547,"completion":43,"start":210,"enrollment":1276,"conditions":2823,"interventions":2824},[86],[2804],[2789,2806],{"trials":2826,"activeCount":96},[],{"trials":2828,"activeCount":96},[],{"intervention":2830,"totalTrials":92,"cells":2831},"Balanced general anesthesia without morphine",{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2836,"PHASE3":2838,"PHASE4":2851,"NA":2853},{"trials":2833,"activeCount":96},[],{"trials":2835,"activeCount":96},[],{"trials":2837,"activeCount":96},[],{"trials":2839,"activeCount":96},[2840],{"nctId":2841,"briefTitle":2842,"status":161,"phases":2843,"primaryCompletion":2844,"completion":2844,"start":2845,"enrollment":2846,"conditions":2847,"interventions":2849},"NCT04886453","Evaluation of Non-opioid Balanced General Anesthesia in Cardiac Surgery With Extracorporeal Circulation: a Randomized, Controlled, Multicenter Superiority Trial",[86],"2024-03-21","2021-08-30",321,[2848,2442],"Opioid-free Anesthesia",[2830,2850],"Standard general anesthesia balanced with morphine",{"trials":2852,"activeCount":96},[],{"trials":2854,"activeCount":96},[],{"intervention":2850,"totalTrials":92,"cells":2856},{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2869,"NA":2871},{"trials":2858,"activeCount":96},[],{"trials":2860,"activeCount":96},[],{"trials":2862,"activeCount":96},[],{"trials":2864,"activeCount":96},[2865],{"nctId":2841,"briefTitle":2842,"status":161,"phases":2866,"primaryCompletion":2844,"completion":2844,"start":2845,"enrollment":2846,"conditions":2867,"interventions":2868},[86],[2848,2442],[2830,2850],{"trials":2870,"activeCount":96},[],{"trials":2872,"activeCount":96},[],{"intervention":157,"totalTrials":447,"cells":2874},{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2876,"activeCount":96},[],{"trials":2878,"activeCount":96},[],{"trials":2880,"activeCount":96},[2881,2885],{"nctId":147,"briefTitle":148,"status":149,"phases":2882,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":2883,"interventions":2884},[85],[155],[157,54],{"nctId":159,"briefTitle":160,"status":161,"phases":2886,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":2887,"interventions":2888},[85],[167],[169,157,54],{"trials":2890,"activeCount":96},[],{"trials":2892,"activeCount":96},[],{"trials":2894,"activeCount":96},[],{"intervention":2896,"totalTrials":92,"cells":2897},"5 ml Ropivacaine 10% + physiological saline",{"EARLY_PHASE1":2898,"PHASE1":2900,"PHASE2":2902,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2899,"activeCount":96},[],{"trials":2901,"activeCount":96},[],{"trials":2903,"activeCount":96},[2904],{"nctId":2905,"briefTitle":2906,"status":161,"phases":2907,"primaryCompletion":1254,"completion":1254,"start":2908,"enrollment":268,"conditions":2909,"interventions":2911},"NCT01963299","Clonidine - Ropivacaine in Peribulbar Anesthesia",[85],"2013-08-16",[2910],"Indication for Surgery of the Posterior Segment Under Locoregional Anaesthesia",[2896,2912],"5 ml Ropivacaine 10% + Clonidine 1 µg\u002Fkg",{"trials":2914,"activeCount":96},[],{"trials":2916,"activeCount":96},[],{"trials":2918,"activeCount":96},[],{"intervention":2912,"totalTrials":92,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2922,"activeCount":96},[],{"trials":2924,"activeCount":96},[],{"trials":2926,"activeCount":96},[2927],{"nctId":2905,"briefTitle":2906,"status":161,"phases":2928,"primaryCompletion":1254,"completion":1254,"start":2908,"enrollment":268,"conditions":2929,"interventions":2930},[85],[2910],[2896,2912],{"trials":2932,"activeCount":96},[],{"trials":2934,"activeCount":96},[],{"trials":2936,"activeCount":96},[],{"intervention":2938,"totalTrials":92,"cells":2939},"Sirolimus",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2954,"PHASE4":2956,"NA":2958},{"trials":2941,"activeCount":96},[],{"trials":2943,"activeCount":96},[],{"trials":2945,"activeCount":96},[2946],{"nctId":2947,"briefTitle":2948,"status":161,"phases":2949,"primaryCompletion":2950,"completion":2950,"start":342,"enrollment":2527,"conditions":2951,"interventions":2953},"NCT02443818","Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA",[85],"2016-11",[2952],"Segmental Overgrowth Disorders Due to PIK3CA",[2938],{"trials":2955,"activeCount":96},[],{"trials":2957,"activeCount":96},[],{"trials":2959,"activeCount":96},[],{"intervention":2961,"totalTrials":92,"cells":2962},"LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified",{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2980,"PHASE4":2982,"NA":2984},{"trials":2964,"activeCount":96},[],{"trials":2966,"activeCount":96},[],{"trials":2968,"activeCount":96},[2969],{"nctId":2970,"briefTitle":2971,"status":161,"phases":2972,"primaryCompletion":342,"completion":2973,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2978},"NCT01900717","Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)",[85],"2016-03","2011-07",102,[2977],"Metastatic Colorectal Adenocarcinoma",[2961,2979],"LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg\u002Fkg\u002F 2 weeks",{"trials":2981,"activeCount":96},[],{"trials":2983,"activeCount":96},[],{"trials":2985,"activeCount":96},[],{"intervention":2979,"totalTrials":92,"cells":2987},{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":2998,"PHASE4":3000,"NA":3002},{"trials":2989,"activeCount":96},[],{"trials":2991,"activeCount":96},[],{"trials":2993,"activeCount":96},[2994],{"nctId":2970,"briefTitle":2971,"status":161,"phases":2995,"primaryCompletion":342,"completion":2973,"start":2974,"enrollment":2975,"conditions":2996,"interventions":2997},[85],[2977],[2961,2979],{"trials":2999,"activeCount":96},[],{"trials":3001,"activeCount":96},[],{"trials":3003,"activeCount":96},[],{"intervention":3005,"totalTrials":92,"cells":3006},"Daptomycin",{"EARLY_PHASE1":3007,"PHASE1":3009,"PHASE2":3011,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3008,"activeCount":96},[],{"trials":3010,"activeCount":96},[],{"trials":3012,"activeCount":96},[3013],{"nctId":3014,"briefTitle":3015,"status":161,"phases":3016,"primaryCompletion":3017,"completion":3018,"start":3019,"enrollment":3020,"conditions":3021,"interventions":3023},"NCT03480191","Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis",[85],"2024-05-11","2024-08-21","2018-06-07",112,[3022],"Pneumococcal Meningitis",[3005],{"trials":3025,"activeCount":96},[],{"trials":3027,"activeCount":96},[],{"trials":3029,"activeCount":96},[],{"intervention":181,"totalTrials":92,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3036,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3033,"activeCount":96},[],{"trials":3035,"activeCount":96},[],{"trials":3037,"activeCount":96},[3038],{"nctId":171,"briefTitle":172,"status":149,"phases":3039,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":3040,"interventions":3041},[85],[179],[181,54],{"trials":3043,"activeCount":96},[],{"trials":3045,"activeCount":96},[],{"trials":3047,"activeCount":96},[],{"intervention":3049,"totalTrials":92,"cells":3050},"corticoids+ tocilizumab 8mg\u002FKg\u002F4 weeks",{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3065,"PHASE4":3067,"NA":3069},{"trials":3052,"activeCount":96},[],{"trials":3054,"activeCount":96},[],{"trials":3056,"activeCount":96},[3057],{"nctId":3058,"briefTitle":3059,"status":161,"phases":3060,"primaryCompletion":3061,"completion":2079,"start":3062,"enrollment":1102,"conditions":3063,"interventions":3064},"NCT01910038","Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.",[85],"2015-12","2013-11-08",[203],[3049],{"trials":3066,"activeCount":96},[],{"trials":3068,"activeCount":96},[],{"trials":3070,"activeCount":96},[],{"intervention":3072,"totalTrials":92,"cells":3073},"Ceftobiprole Medocaril",{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3092,"PHASE4":3094,"NA":3096},{"trials":3075,"activeCount":96},[],{"trials":3077,"activeCount":96},[],{"trials":3079,"activeCount":96},[3080],{"nctId":3081,"briefTitle":3082,"status":161,"phases":3083,"primaryCompletion":3084,"completion":3085,"start":3086,"enrollment":1374,"conditions":3087,"interventions":3091},"NCT03317093","Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device",[85],"2019-10-21","2019-11-04","2018-03-29",[3088,3089,3090],"Inflamed Meninges","Suspected Meningitis","Ventriculitis",[3072],{"trials":3093,"activeCount":96},[],{"trials":3095,"activeCount":96},[],{"trials":3097,"activeCount":96},[],{"intervention":3099,"totalTrials":92,"cells":3100},"Taselisib",{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3102,"activeCount":96},[],{"trials":3104,"activeCount":96},[],{"trials":3106,"activeCount":96},[3107],{"nctId":3108,"briefTitle":3109,"status":149,"phases":3110,"primaryCompletion":3111,"completion":3085,"start":3112,"enrollment":3113,"conditions":3114,"interventions":3116},"NCT03290092","Trial of Taselisib in Overgrowth",[84,85],"2019-02-14","2017-07-31",19,[3115],"PIK3CA-Related Overgrowth",[3099,3099],{"trials":3118,"activeCount":96},[],{"trials":3120,"activeCount":96},[],{"trials":3122,"activeCount":96},[],{"intervention":3124,"totalTrials":92,"cells":3125},"Injections of OM-174",{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3139,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3127,"activeCount":96},[],{"trials":3129,"activeCount":96},[3130],{"nctId":3131,"briefTitle":3132,"status":161,"phases":3133,"primaryCompletion":3134,"start":3135,"enrollment":257,"conditions":3136,"interventions":3138},"NCT01800812","Effects of OM-174 in Adult Patients With Solid Tumors",[84],"2008-01","2007-03",[3137],"Solid Tumors",[3124],{"trials":3140,"activeCount":96},[],{"trials":3142,"activeCount":96},[],{"trials":3144,"activeCount":96},[],{"trials":3146,"activeCount":96},[],{"intervention":3148,"totalTrials":92,"cells":3149},"Zavedos®",{"EARLY_PHASE1":3150,"PHASE1":3152,"PHASE2":3165,"PHASE3":3167,"PHASE4":3169,"NA":3171},{"trials":3151,"activeCount":96},[],{"trials":3153,"activeCount":96},[3154],{"nctId":3155,"briefTitle":3156,"status":161,"phases":3157,"primaryCompletion":3158,"completion":3159,"start":3160,"enrollment":153,"conditions":3161,"interventions":3164},"NCT02028949","Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study",[84],"2015-11","2016-02-05","2012-11-22",[3162,3163],"Unresectable Non-metastatic Hepatocellular Carcinoma","Child A\u002FB7 Cirrhosis",[3148],{"trials":3166,"activeCount":96},[],{"trials":3168,"activeCount":96},[],{"trials":3170,"activeCount":96},[],{"trials":3172,"activeCount":96},[],{"intervention":3174,"totalTrials":92,"cells":3175},"Ceftaroline fosamil",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3189,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3177,"activeCount":96},[],{"trials":3179,"activeCount":96},[3180],{"nctId":3181,"briefTitle":3182,"status":161,"phases":3183,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":1419,"conditions":3186,"interventions":3188},"NCT02806882","Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)",[84],"2016-10-24","2015-04-29",[3187,3090],"Meningitis",[3174],{"trials":3190,"activeCount":96},[],{"trials":3192,"activeCount":96},[],{"trials":3194,"activeCount":96},[],{"trials":3196,"activeCount":96},[],{"intervention":3198,"totalTrials":92,"cells":3199},"idarubicin",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3215,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3201,"activeCount":96},[],{"trials":3203,"activeCount":96},[3204],{"nctId":3205,"briefTitle":3206,"status":161,"phases":3207,"primaryCompletion":3208,"completion":3209,"start":3210,"enrollment":3211,"conditions":3212,"interventions":3214},"NCT01040559","Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas",[84],"2011-12","2012-06","2009-12",18,[3213],"Carcinoma, Hepatocellular",[3198],{"trials":3216,"activeCount":96},[],{"trials":3218,"activeCount":96},[],{"trials":3220,"activeCount":96},[],{"trials":3222,"activeCount":96},[],{"intervention":3224,"totalTrials":92,"cells":3225},"blood samples (5 ml) will be taken",{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3239,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3227,"activeCount":96},[],{"trials":3229,"activeCount":96},[3230],{"nctId":3231,"briefTitle":3232,"status":161,"phases":3233,"primaryCompletion":3234,"start":3235,"enrollment":373,"conditions":3236,"interventions":3238},"NCT02870010","Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres",[84],"2012-05","2010-02",[3237],"Localized Non-Resectable Adult Hepatocellular Carcinoma",[3224],{"trials":3240,"activeCount":96},[],{"trials":3242,"activeCount":96},[],{"trials":3244,"activeCount":96},[],{"trials":3246,"activeCount":96},[],{"intervention":1332,"totalTrials":216,"cells":3248},{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3273},{"trials":3250,"activeCount":96},[],{"trials":3252,"activeCount":96},[],{"trials":3254,"activeCount":96},[],{"trials":3256,"activeCount":96},[],{"trials":3258,"activeCount":96},[3259,3263],{"nctId":1324,"briefTitle":1325,"status":149,"phases":3260,"primaryCompletion":1327,"start":1328,"enrollment":1329,"conditions":3261,"interventions":3262},[87],[18],[1332,1333,1334],{"nctId":3264,"briefTitle":3265,"status":149,"phases":3266,"primaryCompletion":3267,"completion":3267,"start":3268,"enrollment":3269,"conditions":3270,"interventions":3272},"NCT02674893","Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes",[87],"2016-08-31","2014-02-04",48,[18,3271],"Overweight",[1332],{"trials":3274,"activeCount":96},[3275],{"nctId":3276,"briefTitle":3277,"status":161,"phases":3278,"primaryCompletion":3279,"completion":3280,"start":3279,"enrollment":9,"conditions":3281,"interventions":3283},"NCT01599338","Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients",[88],"2011-01","2011-09",[3282,3271],"Type 2 Diabetes Mellitus",[1332],{"intervention":3285,"totalTrials":447,"cells":3286},"prise de sang",{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3288,"activeCount":96},[],{"trials":3290,"activeCount":96},[],{"trials":3292,"activeCount":96},[],{"trials":3294,"activeCount":96},[],{"trials":3296,"activeCount":96},[],{"trials":3298,"activeCount":96},[3299,3309],{"nctId":3300,"briefTitle":3301,"status":161,"phases":3302,"primaryCompletion":3303,"completion":3304,"start":3305,"enrollment":3306,"conditions":3307,"interventions":3308},"NCT02856074","Functional Prognosis in Patients With Ischemic Stroke According to the Therapeutic Strategy Used",[88],"2019-06-11","2020-06-01","2016-01-13",821,[356],[3285],{"nctId":3310,"briefTitle":3311,"status":161,"phases":3312,"primaryCompletion":3313,"completion":3313,"start":1372,"enrollment":3314,"conditions":3315,"interventions":3317},"NCT02816099","Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients",[88],"2022-11-14",206,[3316],"diabète de Type 1",[3318],"Prise de sang",{"intervention":3320,"totalTrials":447,"cells":3321},"Biological data",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3328,"PHASE4":3330,"NA":3332},{"trials":3323,"activeCount":96},[],{"trials":3325,"activeCount":96},[],{"trials":3327,"activeCount":96},[],{"trials":3329,"activeCount":96},[],{"trials":3331,"activeCount":96},[],{"trials":3333,"activeCount":96},[3334,3345],{"nctId":3335,"briefTitle":3336,"status":330,"phases":3337,"primaryCompletion":3338,"completion":3339,"start":3340,"enrollment":3341,"conditions":3342,"interventions":3344},"NCT04498091","EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19",[],"2020-07-01","2021-07","2020-03-15",35,[3343],"Acute Myocardial Infarction",[3320],{"nctId":3346,"briefTitle":3347,"status":161,"phases":3348,"primaryCompletion":3349,"completion":3349,"start":3350,"enrollment":3351,"conditions":3352,"interventions":3357},"NCT04498065","MYocardial DOmmages Related to COVID-19",[],"2022-05-31","2020-03-01",273,[3353,3354,1487,3355,3356],"Covid19","Non Ischemic Myocardial Injury","Myocarditis","Troponin Elevation",[3320],{"intervention":3359,"totalTrials":447,"cells":3360},"High-throughput exome sequencing",{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3365,"PHASE3":3367,"PHASE4":3369,"NA":3371},{"trials":3362,"activeCount":96},[],{"trials":3364,"activeCount":96},[],{"trials":3366,"activeCount":96},[],{"trials":3368,"activeCount":96},[],{"trials":3370,"activeCount":96},[],{"trials":3372,"activeCount":96},[3373,3381],{"nctId":3374,"briefTitle":3375,"status":161,"phases":3376,"primaryCompletion":1467,"start":3377,"enrollment":1477,"conditions":3378,"interventions":3380},"NCT02866162","Screening for Genes in Patients With Congenital Neutropenia",[],"2013-09",[3379],"Congenital Neutropenia",[3359],{"nctId":3382,"briefTitle":3383,"status":161,"phases":3384,"primaryCompletion":1467,"start":3385,"enrollment":3386,"conditions":3387,"interventions":3389},"NCT02862834","Screening for Genes in Patients With Poikiloderma",[],"2013-05",39,[3388],"Poikiloderma",[3359],{"intervention":3391,"totalTrials":447,"cells":3392},"Blood and urine samples",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3399,"PHASE4":3401,"NA":3403},{"trials":3394,"activeCount":96},[],{"trials":3396,"activeCount":96},[],{"trials":3398,"activeCount":96},[],{"trials":3400,"activeCount":96},[],{"trials":3402,"activeCount":96},[],{"trials":3404,"activeCount":96},[3405,3416],{"nctId":3406,"briefTitle":3407,"status":161,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":3411,"conditions":3412,"interventions":3415},"NCT04375358","Creatinine Clearance as a Predictor of Successful Withdrawl of Continuous Renal Replacement Therapy in Intensive Care",[],"2021-03-30","2018-10-01",64,[3413,3414],"Dialysis Withdrawal","Creatinine Clearance",[3391],{"nctId":3417,"briefTitle":3418,"status":330,"phases":3419,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":268,"conditions":3422,"interventions":3424},"NCT05099211","Neuromuscular Deconditioning and Reconditioning in Colon Cancer Patients: an APA Muscle Rendorcement Program",[88],"2025-01","2022-07",[33,3423],"Muscle Strengthening",[3391],{"intervention":3426,"totalTrials":447,"cells":3427},"Sampling of blood",{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3429,"activeCount":96},[],{"trials":3431,"activeCount":96},[],{"trials":3433,"activeCount":96},[],{"trials":3435,"activeCount":96},[],{"trials":3437,"activeCount":96},[],{"trials":3439,"activeCount":96},[3440,3449],{"nctId":3441,"briefTitle":3442,"status":161,"phases":3443,"primaryCompletion":3444,"completion":3444,"start":3445,"enrollment":1923,"conditions":3446,"interventions":3448},"NCT01931800","Identification and Quantification of Immune Response Induced by Hyaluronidase and Other Factors of Virulence of Invasive Human Infections of Streptococcus Pneumoniae",[],"2015-01-27","2005-01-06",[3447],"Invasive Pneumococcic",[3426],{"nctId":3450,"briefTitle":3451,"status":330,"phases":3452,"primaryCompletion":3453,"start":3454,"enrollment":3455,"conditions":3456,"interventions":3458},"NCT01962129","Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene",[],"2014-06","2011-06",133,[3457],"Orofaciodigital Syndromes",[3426],{"intervention":3460,"totalTrials":447,"cells":3461},"blood collection",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3463,"activeCount":96},[],{"trials":3465,"activeCount":96},[],{"trials":3467,"activeCount":96},[],{"trials":3469,"activeCount":96},[],{"trials":3471,"activeCount":96},[],{"trials":3473,"activeCount":96},[3474,3485],{"nctId":3475,"briefTitle":3476,"status":330,"phases":3477,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":3480,"conditions":3481,"interventions":3484},"NCT05110547","Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions",[],"2023-04","2021-04-27",75,[3482,3483],"Idiopathic Parkinson Disease","Parkinsonian Syndrome",[3460],{"nctId":3486,"briefTitle":3487,"status":161,"phases":3488,"primaryCompletion":3489,"completion":3489,"start":3490,"enrollment":9,"conditions":3491,"interventions":3492},"NCT04659018","Development of a Serum Test for Colorectal Cancer Screening (COLODIAG préclinique)",[],"2022-08-11","2020-08-24",[28],[3460],{"intervention":3494,"totalTrials":92,"cells":3495},"Induction and maintenance of anesthesia",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3497,"activeCount":96},[],{"trials":3499,"activeCount":96},[],{"trials":3501,"activeCount":96},[],{"trials":3503,"activeCount":96},[],{"trials":3505,"activeCount":96},[],{"trials":3507,"activeCount":96},[3508],{"nctId":3509,"briefTitle":3510,"status":161,"phases":3511,"primaryCompletion":3512,"completion":3512,"start":3513,"enrollment":354,"conditions":3514,"interventions":3517},"NCT03864016","Ability of Pupillometry to Reduce Sufentanil Consumption in Planned Cardiac Surgery: Randomized, Controlled, Single-center Clinical Superiority Trial",[88],"2019-10-22","2019-03-20",[3515,3516],"Patients Undergoing Cardiac Surgery","Patients With Coronary Artery Bypass Surgery With CEC",[3494,3518,3519],"Adaptation of sufentanil doses according to the usual protocol","Adjustment of sufentanil doses according to pupillometry",{"intervention":3518,"totalTrials":92,"cells":3521},{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3523,"activeCount":96},[],{"trials":3525,"activeCount":96},[],{"trials":3527,"activeCount":96},[],{"trials":3529,"activeCount":96},[],{"trials":3531,"activeCount":96},[],{"trials":3533,"activeCount":96},[3534],{"nctId":3509,"briefTitle":3510,"status":161,"phases":3535,"primaryCompletion":3512,"completion":3512,"start":3513,"enrollment":354,"conditions":3536,"interventions":3537},[88],[3515,3516],[3494,3518,3519],{"intervention":3519,"totalTrials":92,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3544,"PHASE3":3546,"PHASE4":3548,"NA":3550},{"trials":3541,"activeCount":96},[],{"trials":3543,"activeCount":96},[],{"trials":3545,"activeCount":96},[],{"trials":3547,"activeCount":96},[],{"trials":3549,"activeCount":96},[],{"trials":3551,"activeCount":96},[3552],{"nctId":3509,"briefTitle":3510,"status":161,"phases":3553,"primaryCompletion":3512,"completion":3512,"start":3513,"enrollment":354,"conditions":3554,"interventions":3555},[88],[3515,3516],[3494,3518,3519],{"intervention":3557,"totalTrials":92,"cells":3558},"cortisone aerosol",{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3563,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3560,"activeCount":96},[],{"trials":3562,"activeCount":96},[],{"trials":3564,"activeCount":96},[],{"trials":3566,"activeCount":96},[],{"trials":3568,"activeCount":96},[],{"trials":3570,"activeCount":96},[3571],{"nctId":3572,"briefTitle":3573,"status":161,"phases":3574,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":3578,"interventions":3581},"NCT02855866","Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy",[88],"2015-02-20","2013-09-03",240,[3579,3580],"Thyroidectomy","Post-operative Swallowing Disorders",[3557,3582,3583],"Dexamethasone acetate","paracetamol",{"intervention":3582,"totalTrials":92,"cells":3585},{"EARLY_PHASE1":3586,"PHASE1":3588,"PHASE2":3590,"PHASE3":3592,"PHASE4":3594,"NA":3596},{"trials":3587,"activeCount":96},[],{"trials":3589,"activeCount":96},[],{"trials":3591,"activeCount":96},[],{"trials":3593,"activeCount":96},[],{"trials":3595,"activeCount":96},[],{"trials":3597,"activeCount":96},[3598],{"nctId":3572,"briefTitle":3573,"status":161,"phases":3599,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":3600,"interventions":3601},[88],[3579,3580],[3557,3582,3583],{"intervention":3583,"totalTrials":92,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3605,"activeCount":96},[],{"trials":3607,"activeCount":96},[],{"trials":3609,"activeCount":96},[],{"trials":3611,"activeCount":96},[],{"trials":3613,"activeCount":96},[],{"trials":3615,"activeCount":96},[3616],{"nctId":3572,"briefTitle":3573,"status":161,"phases":3617,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":3618,"interventions":3619},[88],[3579,3580],[3557,3582,3583],{"intervention":3621,"totalTrials":92,"cells":3622},"pyrosequencing",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3624,"activeCount":96},[],{"trials":3626,"activeCount":96},[],{"trials":3628,"activeCount":96},[],{"trials":3630,"activeCount":96},[],{"trials":3632,"activeCount":96},[],{"trials":3634,"activeCount":96},[3635],{"nctId":3636,"briefTitle":3637,"status":161,"phases":3638,"primaryCompletion":1524,"start":342,"enrollment":19,"conditions":3639,"interventions":3641},"NCT02859688","Can Epimutations be Inherited? How to Manage Patients With Imprinting-related Diseases Who Wish to Become Parents",[],[3640],"Epimutation",[3621,3642],"Methylome",{"intervention":3642,"totalTrials":92,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3651,"PHASE4":3653,"NA":3655},{"trials":3646,"activeCount":96},[],{"trials":3648,"activeCount":96},[],{"trials":3650,"activeCount":96},[],{"trials":3652,"activeCount":96},[],{"trials":3654,"activeCount":96},[],{"trials":3656,"activeCount":96},[3657],{"nctId":3636,"briefTitle":3637,"status":161,"phases":3658,"primaryCompletion":1524,"start":342,"enrollment":19,"conditions":3659,"interventions":3660},[],[3640],[3621,3642],{"intervention":3662,"totalTrials":92,"cells":3663},"Blood tests",{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3665,"activeCount":96},[],{"trials":3667,"activeCount":96},[],{"trials":3669,"activeCount":96},[],{"trials":3671,"activeCount":96},[],{"trials":3673,"activeCount":96},[],{"trials":3675,"activeCount":96},[3676],{"nctId":3677,"briefTitle":3678,"status":161,"phases":3679,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":2263,"conditions":3682,"interventions":3684},"NCT04886180","Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO\u002FECLS): A Randomized Pilot Study ECMORIX",[88],"2023-03-10","2021-05-18",[3683],"Cardiogenic Shock",[3662],{"intervention":3686,"totalTrials":92,"cells":3687},"analysis (protein, lipid, RNA ...) of circulating exosomes, size and number",{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3694,"PHASE4":3696,"NA":3698},{"trials":3689,"activeCount":96},[],{"trials":3691,"activeCount":96},[],{"trials":3693,"activeCount":96},[],{"trials":3695,"activeCount":96},[],{"trials":3697,"activeCount":96},[],{"trials":3699,"activeCount":96},[3700],{"nctId":3701,"briefTitle":3702,"status":149,"phases":3703,"primaryCompletion":3704,"completion":3704,"start":3338,"enrollment":3705,"conditions":3706,"interventions":3707},"NCT04523389","Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients",[],"2026-03-18",172,[28],[3686],{"intervention":3709,"totalTrials":92,"cells":3710},"Peripheral blood samples in EDTA tubes",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3712,"activeCount":96},[],{"trials":3714,"activeCount":96},[],{"trials":3716,"activeCount":96},[],{"trials":3718,"activeCount":96},[],{"trials":3720,"activeCount":96},[],{"trials":3722,"activeCount":96},[3723],{"nctId":3724,"briefTitle":3725,"status":161,"phases":3726,"primaryCompletion":3727,"start":3728,"enrollment":3729,"conditions":3730,"interventions":3732},"NCT01950975","Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism.",[88],"2017-09-08","2012-02-20",315,[3731],"Malformations With Skin Manifestations Suggesting Mosaicism",[3709],{"intervention":249,"totalTrials":92,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3741,"PHASE4":3743,"NA":3745},{"trials":3736,"activeCount":96},[],{"trials":3738,"activeCount":96},[],{"trials":3740,"activeCount":96},[],{"trials":3742,"activeCount":96},[],{"trials":3744,"activeCount":96},[],{"trials":3746,"activeCount":96},[3747],{"nctId":240,"briefTitle":241,"status":161,"phases":3748,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":3749,"interventions":3750},[],[247],[249,250],{"intervention":3752,"totalTrials":92,"cells":3753},"Assessing the blood level of cholesterol 24 S Hydroxylase",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3755,"activeCount":96},[],{"trials":3757,"activeCount":96},[],{"trials":3759,"activeCount":96},[],{"trials":3761,"activeCount":96},[],{"trials":3763,"activeCount":96},[],{"trials":3765,"activeCount":96},[3766],{"nctId":3767,"briefTitle":3768,"status":161,"phases":3769,"primaryCompletion":3770,"completion":3279,"start":3771,"enrollment":3772,"conditions":3773,"interventions":3775},"NCT00629044","Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD",[88],"2009-11","2007-11",320,[3774],"Glaucoma",[3752,3776,3777],"Assessing the blood level of cholesterol 24 S hydroxylase","assessing the blood level of cholesterol 24 S hydroxylase",{"intervention":3779,"totalTrials":92,"cells":3780},"blood samples from children",{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3787,"PHASE4":3789,"NA":3791},{"trials":3782,"activeCount":96},[],{"trials":3784,"activeCount":96},[],{"trials":3786,"activeCount":96},[],{"trials":3788,"activeCount":96},[],{"trials":3790,"activeCount":96},[],{"trials":3792,"activeCount":96},[3793],{"nctId":3794,"briefTitle":3795,"status":161,"phases":3796,"primaryCompletion":362,"completion":3797,"start":3798,"enrollment":3799,"conditions":3800,"interventions":3802},"NCT03287206","Medico-economic Evaluation of Different High-throughput Sequencing Strategies in the Diagnosis of Patients With Intellectual Deficiency",[],"2023-12-16","2017-06-28",337,[3801],"Intellectual Deficiency",[3779,3803],"blood samples from parents",{"intervention":3803,"totalTrials":92,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3810,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3807,"activeCount":96},[],{"trials":3809,"activeCount":96},[],{"trials":3811,"activeCount":96},[],{"trials":3813,"activeCount":96},[],{"trials":3815,"activeCount":96},[],{"trials":3817,"activeCount":96},[3818],{"nctId":3794,"briefTitle":3795,"status":161,"phases":3819,"primaryCompletion":362,"completion":3797,"start":3798,"enrollment":3799,"conditions":3820,"interventions":3821},[],[3801],[3779,3803],{"intervention":3823,"totalTrials":92,"cells":3824},"Aldosterone \u002F renin dosage",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3829,"PHASE3":3831,"PHASE4":3833,"NA":3835},{"trials":3826,"activeCount":96},[],{"trials":3828,"activeCount":96},[],{"trials":3830,"activeCount":96},[],{"trials":3832,"activeCount":96},[],{"trials":3834,"activeCount":96},[],{"trials":3836,"activeCount":96},[3837],{"nctId":3838,"briefTitle":3839,"status":161,"phases":3840,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":2263,"conditions":3843,"interventions":3844},"NCT03258619","Natriuresis as a Predictor of the Haemodynamic Response to Steroid Replacement Therapy in Patients in Septic Shock",[],"2017-11-15","2017-02-27",[23],[3823,3845],"Natriuresis",{"intervention":3845,"totalTrials":92,"cells":3847},{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3852,"PHASE3":3854,"PHASE4":3856,"NA":3858},{"trials":3849,"activeCount":96},[],{"trials":3851,"activeCount":96},[],{"trials":3853,"activeCount":96},[],{"trials":3855,"activeCount":96},[],{"trials":3857,"activeCount":96},[],{"trials":3859,"activeCount":96},[3860],{"nctId":3838,"briefTitle":3839,"status":161,"phases":3861,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":2263,"conditions":3862,"interventions":3863},[],[23],[3823,3845],{"intervention":3865,"totalTrials":92,"cells":3866},"microbiological characterization",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3873,"PHASE4":3875,"NA":3877},{"trials":3868,"activeCount":96},[],{"trials":3870,"activeCount":96},[],{"trials":3872,"activeCount":96},[],{"trials":3874,"activeCount":96},[],{"trials":3876,"activeCount":96},[],{"trials":3878,"activeCount":96},[3879],{"nctId":3880,"briefTitle":3881,"status":161,"phases":3882,"primaryCompletion":3883,"completion":3883,"start":3884,"enrollment":323,"conditions":3885,"interventions":3889},"NCT04926493","Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Patients at Increased Risk for the Development of Ventilator-associated Pneumonia in the Intensive Care Unit",[],"2021-07-31","2021-05-01",[3886,3887,3888],"Biofilm Formation","Structural and Microbiological Characterization of Endotracheal Tube Biofilm","Ventilator-associated Pneumonia (VAP)",[3865],{"intervention":3891,"totalTrials":92,"cells":3892},"Blood sample taken on the day the treatment is initiated",{"EARLY_PHASE1":3893,"PHASE1":3895,"PHASE2":3897,"PHASE3":3899,"PHASE4":3901,"NA":3903},{"trials":3894,"activeCount":96},[],{"trials":3896,"activeCount":96},[],{"trials":3898,"activeCount":96},[],{"trials":3900,"activeCount":96},[],{"trials":3902,"activeCount":96},[],{"trials":3904,"activeCount":96},[3905],{"nctId":3906,"briefTitle":3907,"status":161,"phases":3908,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":2193,"conditions":3911,"interventions":3913},"NCT02333448","Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the \"Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis.",[],"2019-09-17","2015-06-12",[3912],"Invasive Candidiasis; Treatment With Echinocandin",[3891,3914,3915,3916,3917],"Blood sample taken on day 3 after initiation of treatment","Blood sample taken on day 5 after initiation of","Blood sample taken on day 7 after initiation of treatment","Blood sample taken on day 10 after initiation of treatment",{"intervention":3914,"totalTrials":92,"cells":3919},{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3930},{"trials":3921,"activeCount":96},[],{"trials":3923,"activeCount":96},[],{"trials":3925,"activeCount":96},[],{"trials":3927,"activeCount":96},[],{"trials":3929,"activeCount":96},[],{"trials":3931,"activeCount":96},[3932],{"nctId":3906,"briefTitle":3907,"status":161,"phases":3933,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":2193,"conditions":3934,"interventions":3935},[],[3912],[3891,3914,3915,3916,3917],{"intervention":3915,"totalTrials":92,"cells":3937},{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3942,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3939,"activeCount":96},[],{"trials":3941,"activeCount":96},[],{"trials":3943,"activeCount":96},[],{"trials":3945,"activeCount":96},[],{"trials":3947,"activeCount":96},[],{"trials":3949,"activeCount":96},[3950],{"nctId":3906,"briefTitle":3907,"status":161,"phases":3951,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":2193,"conditions":3952,"interventions":3953},[],[3912],[3891,3914,3915,3916,3917],{"intervention":3916,"totalTrials":92,"cells":3955},{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3957,"activeCount":96},[],{"trials":3959,"activeCount":96},[],{"trials":3961,"activeCount":96},[],{"trials":3963,"activeCount":96},[],{"trials":3965,"activeCount":96},[],{"trials":3967,"activeCount":96},[3968],{"nctId":3906,"briefTitle":3907,"status":161,"phases":3969,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":2193,"conditions":3970,"interventions":3971},[],[3912],[3891,3914,3915,3916,3917],{"intervention":3917,"totalTrials":92,"cells":3973},{"EARLY_PHASE1":3974,"PHASE1":3976,"PHASE2":3978,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3975,"activeCount":96},[],{"trials":3977,"activeCount":96},[],{"trials":3979,"activeCount":96},[],{"trials":3981,"activeCount":96},[],{"trials":3983,"activeCount":96},[],{"trials":3985,"activeCount":96},[3986],{"nctId":3906,"briefTitle":3907,"status":161,"phases":3987,"primaryCompletion":3909,"completion":3909,"start":3910,"enrollment":2193,"conditions":3988,"interventions":3989},[],[3912],[3891,3914,3915,3916,3917],{"intervention":3991,"totalTrials":92,"cells":3992},"2 Blood samples from arterial and\u002For central venous catheters",{"EARLY_PHASE1":3993,"PHASE1":3995,"PHASE2":3997,"PHASE3":3999,"PHASE4":4001,"NA":4003},{"trials":3994,"activeCount":96},[],{"trials":3996,"activeCount":96},[],{"trials":3998,"activeCount":96},[],{"trials":4000,"activeCount":96},[],{"trials":4002,"activeCount":96},[],{"trials":4004,"activeCount":96},[4005],{"nctId":4006,"briefTitle":4007,"status":161,"phases":4008,"primaryCompletion":4009,"completion":4009,"start":4010,"enrollment":548,"conditions":4011,"interventions":4013},"NCT05146908","Evaluation of Gastric Echography for Early Diagnosis of Nutritional Intolerance.",[],"2023-04-28","2021-11-29",[4012],"Nutritional Intolerance",[3991],{"intervention":1188,"totalTrials":92,"cells":4015},{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4022,"PHASE4":4024,"NA":4026},{"trials":4017,"activeCount":96},[],{"trials":4019,"activeCount":96},[],{"trials":4021,"activeCount":96},[],{"trials":4023,"activeCount":96},[],{"trials":4025,"activeCount":96},[],{"trials":4027,"activeCount":96},[4028],{"nctId":1177,"briefTitle":1178,"status":161,"phases":4029,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":4030,"interventions":4031},[88],[1184,1185,1186],[1188,1149],{"intervention":4033,"totalTrials":92,"cells":4034},"Extraction of total RNA from healthy and tumour tissues",{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4039,"PHASE3":4041,"PHASE4":4043,"NA":4045},{"trials":4036,"activeCount":96},[],{"trials":4038,"activeCount":96},[],{"trials":4040,"activeCount":96},[],{"trials":4042,"activeCount":96},[],{"trials":4044,"activeCount":96},[],{"trials":4046,"activeCount":96},[4047],{"nctId":4048,"briefTitle":4049,"status":330,"phases":4050,"primaryCompletion":4051,"start":4052,"enrollment":153,"conditions":4053,"interventions":4055},"NCT02873793","Analysis of Transposon Control Pathways in Germinal Cancers of the Testicle",[],"2018-04","2015-04",[4054],"Germinal Cancers of the Testicle",[4033],{"intervention":4057,"totalTrials":92,"cells":4058},"Ondansetron",{"EARLY_PHASE1":4059,"PHASE1":4061,"PHASE2":4063,"PHASE3":4065,"PHASE4":4067,"NA":4069},{"trials":4060,"activeCount":96},[],{"trials":4062,"activeCount":96},[],{"trials":4064,"activeCount":96},[],{"trials":4066,"activeCount":96},[],{"trials":4068,"activeCount":96},[],{"trials":4070,"activeCount":96},[4071],{"nctId":4072,"briefTitle":4073,"status":149,"phases":4074,"primaryCompletion":342,"start":2169,"enrollment":19,"conditions":4075,"interventions":4077},"NCT02862873","Interest of Intravenous Ondansetron in the Prevention of Spinal Anaesthesia-induced Hypotension in Caesarean Section",[88],[4076],"Hypotension",[4057],{"intervention":4079,"totalTrials":92,"cells":4080},"Collection of samples",{"EARLY_PHASE1":4081,"PHASE1":4083,"PHASE2":4085,"PHASE3":4087,"PHASE4":4089,"NA":4091},{"trials":4082,"activeCount":96},[],{"trials":4084,"activeCount":96},[],{"trials":4086,"activeCount":96},[],{"trials":4088,"activeCount":96},[],{"trials":4090,"activeCount":96},[],{"trials":4092,"activeCount":96},[4093],{"nctId":4094,"briefTitle":4095,"status":161,"phases":4096,"primaryCompletion":4097,"completion":4097,"start":4098,"enrollment":3480,"conditions":4099,"interventions":4101},"NCT05182242","Comparison of the Non-invasive Approach and Fetal Exome Sequencing in Prenatal Diagnosis When Fetal Ultrasound Signs Are Discovered",[88],"2024-03-14","2022-03-08",[4100],"Antenatal Congenital Malformations",[4079],{"intervention":4103,"totalTrials":92,"cells":4104},"venipunctures",{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4111,"PHASE4":4113,"NA":4115},{"trials":4106,"activeCount":96},[],{"trials":4108,"activeCount":96},[],{"trials":4110,"activeCount":96},[],{"trials":4112,"activeCount":96},[],{"trials":4114,"activeCount":96},[],{"trials":4116,"activeCount":96},[4117],{"nctId":4118,"briefTitle":4119,"status":149,"phases":4120,"primaryCompletion":4121,"completion":4121,"start":3084,"enrollment":257,"conditions":4122,"interventions":4126},"NCT03745235","A Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders",[88],"2020-02-26",[4123,4124,4125],"Psychiatry","Caregivers","Mindfulness",[4103],{"intervention":4128,"totalTrials":92,"cells":4129},"injection of BEP 800",{"EARLY_PHASE1":4130,"PHASE1":4132,"PHASE2":4134,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4131,"activeCount":96},[],{"trials":4133,"activeCount":96},[],{"trials":4135,"activeCount":96},[],{"trials":4137,"activeCount":96},[],{"trials":4139,"activeCount":96},[],{"trials":4141,"activeCount":96},[4142],{"nctId":4143,"briefTitle":4144,"status":330,"phases":4145,"primaryCompletion":4146,"completion":4146,"start":4147,"enrollment":4148,"conditions":4149,"interventions":4152},"NCT04437420","Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90",[],"2021-09","2019-11-01",44,[4150,4151],"Acute T Lymphoblastic Leukemia (T-ALL)","Acute B Lymphoblastic Leukemia (B-ALL)",[4128],{"intervention":4154,"totalTrials":92,"cells":4155},"Blood sampling at inclusion",{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4162,"PHASE4":4164,"NA":4166},{"trials":4157,"activeCount":96},[],{"trials":4159,"activeCount":96},[],{"trials":4161,"activeCount":96},[],{"trials":4163,"activeCount":96},[],{"trials":4165,"activeCount":96},[],{"trials":4167,"activeCount":96},[4168],{"nctId":4169,"briefTitle":4170,"status":161,"phases":4171,"primaryCompletion":4172,"completion":4172,"start":4173,"enrollment":1215,"conditions":4174,"interventions":4176},"NCT05040503","Monitoring Mitophagy In Myeloid Cells Upon Intensive Care",[88],"2025-03-13","2021-08-25",[4175],"Septicemia",[4154,4177],"Blood sampling at 24 hours",{"intervention":4177,"totalTrials":92,"cells":4179},{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4181,"activeCount":96},[],{"trials":4183,"activeCount":96},[],{"trials":4185,"activeCount":96},[],{"trials":4187,"activeCount":96},[],{"trials":4189,"activeCount":96},[],{"trials":4191,"activeCount":96},[4192],{"nctId":4169,"briefTitle":4170,"status":161,"phases":4193,"primaryCompletion":4172,"completion":4172,"start":4173,"enrollment":1215,"conditions":4194,"interventions":4195},[88],[4175],[4154,4177],{"intervention":4197,"totalTrials":92,"cells":4198},"Ear canal swab",{"EARLY_PHASE1":4199,"PHASE1":4201,"PHASE2":4203,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4200,"activeCount":96},[],{"trials":4202,"activeCount":96},[],{"trials":4204,"activeCount":96},[],{"trials":4206,"activeCount":96},[],{"trials":4208,"activeCount":96},[],{"trials":4210,"activeCount":96},[4211],{"nctId":4212,"briefTitle":4213,"status":330,"phases":4214,"primaryCompletion":4215,"completion":4215,"start":4215,"enrollment":4216,"conditions":4217,"interventions":4221},"NCT04483232","Achromobacter Spp: Description of Epidemiology and Resistance in Chronic Ear Infections and in Healthy Individuals.",[],"2020-08",1800,[4218,4219,4220],"Achromobacter","Epidemiology","Chronic Ear Infection",[4197],{"intervention":4223,"totalTrials":92,"cells":4224},"Patient blood sampling",{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4226,"activeCount":96},[],{"trials":4228,"activeCount":96},[],{"trials":4230,"activeCount":96},[],{"trials":4232,"activeCount":96},[],{"trials":4234,"activeCount":96},[],{"trials":4236,"activeCount":96},[4237],{"nctId":4238,"briefTitle":4239,"status":161,"phases":4240,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":313,"conditions":4244,"interventions":4247},"NCT03857997","Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability",[],"2019-12-27","2021-02-02","2019-02-04",[4245,4246],"Patients With Intellectual Disabilities Without an Obvious Clinical Diagnosis","Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)",[4223,4248],"Parents blood sampling",{"intervention":4248,"totalTrials":92,"cells":4250},{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4259,"NA":4261},{"trials":4252,"activeCount":96},[],{"trials":4254,"activeCount":96},[],{"trials":4256,"activeCount":96},[],{"trials":4258,"activeCount":96},[],{"trials":4260,"activeCount":96},[],{"trials":4262,"activeCount":96},[4263],{"nctId":4238,"briefTitle":4239,"status":161,"phases":4264,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":313,"conditions":4265,"interventions":4266},[],[4245,4246],[4223,4248],{"intervention":4268,"totalTrials":92,"cells":4269},"Invasive fetal sampling, blood sampling of mother and father",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4278,"NA":4280},{"trials":4271,"activeCount":96},[],{"trials":4273,"activeCount":96},[],{"trials":4275,"activeCount":96},[],{"trials":4277,"activeCount":96},[],{"trials":4279,"activeCount":96},[],{"trials":4281,"activeCount":96},[4282],{"nctId":4283,"briefTitle":4284,"status":161,"phases":4285,"primaryCompletion":4286,"completion":1245,"start":4287,"enrollment":4288,"conditions":4289,"interventions":4292},"NCT03964441","ANDDI-PRENATOME - Feasibility Study for a \" Fast \" Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis",[],"2021-12-20","2019-06-20",149,[4290,4291],"Prenatal","Genome-wide High Throughput Sequencing",[4268,4293],"blood sampling from the mother to recover the circulating cell free fetal DNA",{"intervention":4293,"totalTrials":92,"cells":4295},{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4300,"PHASE3":4302,"PHASE4":4304,"NA":4306},{"trials":4297,"activeCount":96},[],{"trials":4299,"activeCount":96},[],{"trials":4301,"activeCount":96},[],{"trials":4303,"activeCount":96},[],{"trials":4305,"activeCount":96},[],{"trials":4307,"activeCount":96},[4308],{"nctId":4283,"briefTitle":4284,"status":161,"phases":4309,"primaryCompletion":4286,"completion":1245,"start":4287,"enrollment":4288,"conditions":4310,"interventions":4311},[],[4290,4291],[4268,4293],{"intervention":4313,"totalTrials":92,"cells":4314},"blood examination",{"EARLY_PHASE1":4315,"PHASE1":4317,"PHASE2":4319,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4316,"activeCount":96},[],{"trials":4318,"activeCount":96},[],{"trials":4320,"activeCount":96},[],{"trials":4322,"activeCount":96},[],{"trials":4324,"activeCount":96},[],{"trials":4326,"activeCount":96},[4327],{"nctId":4328,"briefTitle":4329,"status":161,"phases":4330,"primaryCompletion":4331,"completion":4332,"start":4147,"enrollment":4333,"conditions":4334,"interventions":4336},"NCT04439617","Monitoring of the Mitochondrial Function of Circulating Myeloid Cells in Patients Hospitalized in the Intensive Care Unit of Dijon University Hospital",[],"2020-01-30","2020-03-30",36,[4335],"Septicaemia",[4313],{"intervention":4338,"totalTrials":92,"cells":4339},"Anticoagulants",{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4344,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4341,"activeCount":96},[],{"trials":4343,"activeCount":96},[],{"trials":4345,"activeCount":96},[],{"trials":4347,"activeCount":96},[],{"trials":4349,"activeCount":96},[],{"trials":4351,"activeCount":96},[4352],{"nctId":4353,"briefTitle":4354,"status":161,"phases":4355,"primaryCompletion":4356,"completion":4356,"start":1339,"enrollment":4357,"conditions":4358,"interventions":4359},"NCT03292575","Study of the Follow-up of Stroke Treated With Anticoagulants",[],"2018-12",441,[15],[4338],{"intervention":4361,"totalTrials":92,"cells":4362},"biological assays in particular on the lipid metabolism",{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4367,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4364,"activeCount":96},[],{"trials":4366,"activeCount":96},[],{"trials":4368,"activeCount":96},[],{"trials":4370,"activeCount":96},[],{"trials":4372,"activeCount":96},[],{"trials":4374,"activeCount":96},[4375],{"nctId":4376,"briefTitle":4377,"status":161,"phases":4378,"primaryCompletion":4379,"completion":4379,"start":4380,"enrollment":313,"conditions":4381,"interventions":4384},"NCT04435223","Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen",[],"2020-05-07","2020-04-07",[4382,4383],"COVID-19 Severe Pneumonia","Severe Pneumonia Due to Other Pathogene",[4361],{"intervention":1220,"totalTrials":92,"cells":4386},{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4397},{"trials":4388,"activeCount":96},[],{"trials":4390,"activeCount":96},[],{"trials":4392,"activeCount":96},[],{"trials":4394,"activeCount":96},[],{"trials":4396,"activeCount":96},[],{"trials":4398,"activeCount":96},[4399],{"nctId":1209,"briefTitle":1210,"status":161,"phases":4400,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":1215,"conditions":4401,"interventions":4402},[],[1217],[1219,1220],{"intervention":4404,"totalTrials":92,"cells":4405},"global medium",{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4407,"activeCount":96},[],{"trials":4409,"activeCount":96},[],{"trials":4411,"activeCount":96},[],{"trials":4413,"activeCount":96},[],{"trials":4415,"activeCount":96},[],{"trials":4417,"activeCount":96},[4418],{"nctId":4419,"briefTitle":4420,"status":161,"phases":4421,"primaryCompletion":4422,"completion":4422,"start":3134,"enrollment":4423,"conditions":4424,"interventions":4426},"NCT02586324","Comparison of Two Embryo Culture Media for IVF and ICSI",[88],"2009-03",1000,[4425],"Culture, ICSI, IVF",[4404,4427],"SSM",{"intervention":4427,"totalTrials":92,"cells":4429},{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4434,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4431,"activeCount":96},[],{"trials":4433,"activeCount":96},[],{"trials":4435,"activeCount":96},[],{"trials":4437,"activeCount":96},[],{"trials":4439,"activeCount":96},[],{"trials":4441,"activeCount":96},[4442],{"nctId":4419,"briefTitle":4420,"status":161,"phases":4443,"primaryCompletion":4422,"completion":4422,"start":3134,"enrollment":4423,"conditions":4444,"interventions":4445},[88],[4425],[4404,4427],{"intervention":4447,"totalTrials":92,"cells":4448},"Serum, plasma and DNA samples",{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4455,"PHASE4":4457,"NA":4459},{"trials":4450,"activeCount":96},[],{"trials":4452,"activeCount":96},[],{"trials":4454,"activeCount":96},[],{"trials":4456,"activeCount":96},[],{"trials":4458,"activeCount":96},[],{"trials":4460,"activeCount":96},[4461],{"nctId":4462,"briefTitle":4463,"status":161,"phases":4464,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":4467,"conditions":4468,"interventions":4471},"NCT01798173","Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients",[88],"2018-01-25","2008-06-20",1246,[4469,4470],"Cirrhosis With Hepatocellular Carcinoma","Cirrhosis Without Hepatocellular Carcinoma",[4447],{"intervention":1231,"totalTrials":92,"cells":4473},{"EARLY_PHASE1":4474,"PHASE1":4476,"PHASE2":4478,"PHASE3":4480,"PHASE4":4482,"NA":4484},{"trials":4475,"activeCount":96},[],{"trials":4477,"activeCount":96},[],{"trials":4479,"activeCount":96},[],{"trials":4481,"activeCount":96},[],{"trials":4483,"activeCount":96},[],{"trials":4485,"activeCount":96},[4486],{"nctId":1222,"briefTitle":1223,"status":161,"phases":4487,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":4488,"interventions":4489},[],[1229,23],[1231,1219],{"intervention":1454,"totalTrials":92,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4493,"activeCount":96},[],{"trials":4495,"activeCount":96},[],{"trials":4497,"activeCount":96},[],{"trials":4499,"activeCount":96},[],{"trials":4501,"activeCount":96},[],{"trials":4503,"activeCount":96},[4504],{"nctId":1444,"briefTitle":1445,"status":161,"phases":4505,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":4506,"interventions":4507},[],[1452],[73,1454],{"intervention":4509,"totalTrials":92,"cells":4510},"GLP-1 agonists",{"EARLY_PHASE1":4511,"PHASE1":4513,"PHASE2":4515,"PHASE3":4517,"PHASE4":4519,"NA":4521},{"trials":4512,"activeCount":96},[],{"trials":4514,"activeCount":96},[],{"trials":4516,"activeCount":96},[],{"trials":4518,"activeCount":96},[],{"trials":4520,"activeCount":96},[],{"trials":4522,"activeCount":96},[4523],{"nctId":4524,"briefTitle":4525,"status":161,"phases":4526,"primaryCompletion":4527,"completion":1589,"start":4528,"enrollment":4529,"conditions":4530,"interventions":4532},"NCT03498001","Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging",[88],"2023-06-06","2018-04-16",42,[4531],"Type II Diabetes",[4509],{"intervention":4534,"totalTrials":92,"cells":4535},"glucose meter",{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4537,"activeCount":96},[],{"trials":4539,"activeCount":96},[],{"trials":4541,"activeCount":96},[],{"trials":4543,"activeCount":96},[],{"trials":4545,"activeCount":96},[],{"trials":4547,"activeCount":96},[4548],{"nctId":4549,"briefTitle":4550,"status":161,"phases":4551,"primaryCompletion":4552,"completion":4552,"start":4553,"enrollment":4148,"conditions":4554,"interventions":4556},"NCT03491423","Short and Fast Step Test: Feasibility, Validity and Tolerance of a Functional Evaluation Test of Lactic Anaerobic Capacities in Patients With Coronary Artery Disease",[88],"2019-05-03","2018-06-04",[4555],"Coronary Artery Disease Without Heart Failure",[4534],{"intervention":4558,"totalTrials":92,"cells":4559},"Blood sample of 30 ml",{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4561,"activeCount":96},[],{"trials":4563,"activeCount":96},[],{"trials":4565,"activeCount":96},[],{"trials":4567,"activeCount":96},[],{"trials":4569,"activeCount":96},[],{"trials":4571,"activeCount":96},[4572],{"nctId":4573,"briefTitle":4574,"status":161,"phases":4575,"primaryCompletion":4576,"completion":4576,"start":4577,"enrollment":4578,"conditions":4579,"interventions":4581},"NCT05476224","Qualitative and Functional Investigation of Lipids in Patients With SARS-CoV2 Infection - In Search of Atherogenic Sequelae",[],"2023-04-12","2022-06-14",228,[4580],"SARS-CoV2 Infection",[4558],{"intervention":4583,"totalTrials":92,"cells":4584},"Blood sample collection",{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4589,"PHASE3":4591,"PHASE4":4593,"NA":4595},{"trials":4586,"activeCount":96},[],{"trials":4588,"activeCount":96},[],{"trials":4590,"activeCount":96},[],{"trials":4592,"activeCount":96},[],{"trials":4594,"activeCount":96},[],{"trials":4596,"activeCount":96},[4597],{"nctId":4598,"briefTitle":4599,"status":161,"phases":4600,"primaryCompletion":4601,"completion":4601,"start":4602,"enrollment":3386,"conditions":4603,"interventions":4605},"NCT04410432","Immune Response and Risk of Serious Infection to SARS-Cov2",[],"2021-01-21","2020-09-29",[4604],"SARS Cov2, Immune Response",[4583],{"intervention":4607,"totalTrials":92,"cells":4608},"Plasma collection for EPO assay",{"EARLY_PHASE1":4609,"PHASE1":4611,"PHASE2":4613,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4610,"activeCount":96},[],{"trials":4612,"activeCount":96},[],{"trials":4614,"activeCount":96},[],{"trials":4616,"activeCount":96},[],{"trials":4618,"activeCount":96},[],{"trials":4620,"activeCount":96},[4621],{"nctId":4622,"briefTitle":4623,"status":330,"phases":4624,"primaryCompletion":4625,"completion":4625,"start":4626,"enrollment":2263,"conditions":4627,"interventions":4630},"NCT03957863","Study of Erythropoietin in Newborns and Children",[],"2020-03","2019-03-12",[4628,4629],"Newborn Infant","Child Under One Year of Age",[4607],{"intervention":4632,"totalTrials":92,"cells":4633},"stool samples",{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4640,"PHASE4":4642,"NA":4644},{"trials":4635,"activeCount":96},[],{"trials":4637,"activeCount":96},[],{"trials":4639,"activeCount":96},[],{"trials":4641,"activeCount":96},[],{"trials":4643,"activeCount":96},[],{"trials":4645,"activeCount":96},[4646],{"nctId":4647,"briefTitle":4648,"status":330,"phases":4649,"primaryCompletion":4650,"start":4651,"enrollment":4652,"conditions":4653,"interventions":4655},"NCT02900703","Surveillance of Rotavirus Gastroenteritis",[],"2017-02","2007-02",9000,[4654],"Gastroenteritis",[4632],{"intervention":4657,"totalTrials":92,"cells":4658},"Lipase, amylase and CRP (C-reactive protein) dosages",{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4669},{"trials":4660,"activeCount":96},[],{"trials":4662,"activeCount":96},[],{"trials":4664,"activeCount":96},[],{"trials":4666,"activeCount":96},[],{"trials":4668,"activeCount":96},[],{"trials":4670,"activeCount":96},[4671],{"nctId":4672,"briefTitle":4673,"status":161,"phases":4674,"primaryCompletion":4675,"completion":4675,"start":4676,"enrollment":4677,"conditions":4678,"interventions":4680},"NCT02784990","Study of Pancreatic Enzymes in the Drains as Early Biomarkers of Post-operative Pancreatic Fistula and Its Clinical Repercussions",[],"2020-11-03","2016-06-03",770,[4679],"Pancreatic Fistula",[4657],{"intervention":4682,"totalTrials":92,"cells":4683},"nicotine treatment",{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4690,"PHASE4":4692,"NA":4694},{"trials":4685,"activeCount":96},[],{"trials":4687,"activeCount":96},[],{"trials":4689,"activeCount":96},[],{"trials":4691,"activeCount":96},[],{"trials":4693,"activeCount":96},[],{"trials":4695,"activeCount":96},[4696],{"nctId":4697,"briefTitle":4698,"status":161,"phases":4699,"primaryCompletion":4700,"completion":4700,"start":4701,"enrollment":4702,"conditions":4703,"interventions":4705},"NCT04591743","Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse.",[88],"2022-10-07","2020-06-29",79,[4704],"Smoking Cessation",[4682],{"intervention":4707,"totalTrials":92,"cells":4708},"C-reactive protein and procalcitonin dosages",{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4713,"PHASE3":4715,"PHASE4":4717,"NA":4719},{"trials":4710,"activeCount":96},[],{"trials":4712,"activeCount":96},[],{"trials":4714,"activeCount":96},[],{"trials":4716,"activeCount":96},[],{"trials":4718,"activeCount":96},[],{"trials":4720,"activeCount":96},[4721],{"nctId":4722,"briefTitle":4723,"status":161,"phases":4724,"completion":4725,"start":4726,"enrollment":4727,"conditions":4728,"interventions":4730},"NCT01510314","Inflammatory Markers After COloRectal Surgery)",[88],"2014-07","2011-11",552,[4729],"Infectious Complications After Colorectal Surgery",[4707],{"intervention":4732,"totalTrials":92,"cells":4733},"bronchoalveolar lavage fluid",{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4738,"PHASE3":4740,"PHASE4":4742,"NA":4744},{"trials":4735,"activeCount":96},[],{"trials":4737,"activeCount":96},[],{"trials":4739,"activeCount":96},[],{"trials":4741,"activeCount":96},[],{"trials":4743,"activeCount":96},[],{"trials":4745,"activeCount":96},[4746],{"nctId":4747,"briefTitle":4748,"status":149,"phases":4749,"primaryCompletion":4379,"completion":4379,"start":3303,"enrollment":2484,"conditions":4750,"interventions":4754},"NCT03955887","Mitochondrial Dysfunction of Alveolar and Circulating Immune Cells During Acute Respiratory Distress Syndrome: Impact of Infectious Aggression and Alveolar Stretching as a Result of Mechanical Ventilation.",[],[4751,4752,4753],"Lung Diseases","Mechanical Ventilation","Bronchoalveolar Lavage",[4732,4755],"Venous blood",{"intervention":4755,"totalTrials":92,"cells":4757},{"EARLY_PHASE1":4758,"PHASE1":4760,"PHASE2":4762,"PHASE3":4764,"PHASE4":4766,"NA":4768},{"trials":4759,"activeCount":96},[],{"trials":4761,"activeCount":96},[],{"trials":4763,"activeCount":96},[],{"trials":4765,"activeCount":96},[],{"trials":4767,"activeCount":96},[],{"trials":4769,"activeCount":96},[4770],{"nctId":4747,"briefTitle":4748,"status":149,"phases":4771,"primaryCompletion":4379,"completion":4379,"start":3303,"enrollment":2484,"conditions":4772,"interventions":4773},[],[4751,4752,4753],[4732,4755]]